Sovos Brands, Inc. - Quarter Report: 2023 July (Form 10-Q)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One) | |
☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended July 1, 2023 | |
OR | |
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from ________ to ________
Commission File Number: 001-40837
Sovos Brands, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 81-5119352 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
168 Centennial Parkway, Suite 200
Louisville, CO 80027
(Address of principal executive offices) (zip code)
(720) 316-1225
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading symbol | Name of each exchange on which registered | ||
Common Stock, $0.001 par value per share | SOVO | The Nasdaq Stock Market LLC (Nasdaq Global Select Market) |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Date File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | ☒ | |
Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
Emerging growth company | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of August 4, 2023, there were 101,318,245 shares of common stock, $0.001 par value per share outstanding.
SOVOS BRANDS, INC.
FORM 10-Q
FOR THE QUARTER ENDED JULY 1, 2023
INDEX
2
PART I. Financial Information
Item 1. Financial Statements (Unaudited)
Sovos Brands, Inc.
Condensed Consolidated Balance Sheets
(Unaudited, dollars in thousands, except par value and share data)
| July 1, 2023 |
| December 31, 2022 | |||
ASSETS |
|
|
|
| ||
CURRENT ASSETS: |
|
|
|
| ||
Cash and cash equivalents | $ | 169,625 | $ | 138,654 | ||
Accounts receivable, net |
| 67,891 |
| 87,695 | ||
Inventories, net |
| 107,553 |
| 92,602 | ||
Prepaid expenses and other current assets |
| 8,708 |
| 11,974 | ||
Total current assets |
| 353,777 |
| 330,925 | ||
Property and equipment, net |
| 62,024 |
| 64,317 | ||
Operating lease right-of-use assets | 12,107 | 13,332 | ||||
Goodwill |
| 395,399 |
| 395,399 | ||
Intangible assets, net |
| 340,335 |
| 351,547 | ||
Other long-term assets |
| 2,392 |
| 3,279 | ||
TOTAL ASSETS | $ | 1,166,034 | $ | 1,158,799 | ||
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
| ||
CURRENT LIABILITIES: |
|
|
|
| ||
Accounts payable | $ | 47,155 | $ | 49,264 | ||
Accrued expenses |
| 55,467 |
| 69,571 | ||
Current portion of long-term debt |
| 80 |
| 99 | ||
Current portion of long-term operating lease liabilities | 3,205 | 3,308 | ||||
Total current liabilities |
| 105,907 |
| 122,242 | ||
Long-term debt, net of debt issuance costs |
| 482,824 |
| 482,344 | ||
Deferred income taxes |
| 62,502 |
| 63,644 | ||
Long-term operating lease liabilities | 12,545 | 14,063 | ||||
Other long-term liabilities |
| 550 |
| 483 | ||
TOTAL LIABILITIES |
| 664,328 |
| 682,776 | ||
COMMITMENTS AND CONTINGENCIES (Note 11) |
|
|
|
| ||
STOCKHOLDERS’ EQUITY: |
|
|
|
| ||
Preferred stock, $0.001 par value per share, 10,000,000 shares authorized, no shares issued and outstanding | ||||||
Common stock, $0.001 par value per share, 500,000,000 shares authorized, 101,318,245 and 100,967,910 shares and as of July 1, 2023 and December 31, 2022, respectively |
| 101 |
| 101 | ||
Additional paid-in-capital |
| 589,591 |
| 577,664 | ||
Accumulated deficit |
| (90,056) |
| (103,291) | ||
Accumulated other comprehensive income | 2,070 | 1,549 | ||||
TOTAL STOCKHOLDERS’ EQUITY |
| 501,706 |
| 476,023 | ||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 1,166,034 | $ | 1,158,799 |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
3
Sovos Brands, Inc.
Condensed Consolidated Statements of Operations
(Unaudited, dollars in thousands, except share and per share data)
13 Weeks Ended | 26 Weeks Ended | |||||||||||
| July 1, 2023 |
| June 25, 2022 |
| July 1, 2023 | June 25, 2022 | ||||||
$ | 217,635 | $ | 197,433 | $ | 470,426 | $ | 407,366 | |||||
| 146,928 |
| 142,410 | 328,907 | 298,435 | |||||||
Gross profit |
| 70,707 |
| 55,023 | 141,519 | 108,931 | ||||||
Operating expenses: | ||||||||||||
Selling, general and administrative |
| 47,633 |
| 39,449 | 91,047 | 73,364 | ||||||
Depreciation and amortization |
| 6,004 |
| 7,200 | 11,984 | 14,403 | ||||||
Impairment of goodwill | — | 42,052 | — | 42,052 | ||||||||
Total operating expenses | 53,637 | 88,701 | 103,031 | 129,819 | ||||||||
Operating income (loss) |
| 17,070 |
| (33,678) | 38,488 | (20,888) | ||||||
Interest expense, net |
| 8,678 |
| 5,713 | 17,379 | 11,735 | ||||||
Income (loss) before income taxes |
| 8,392 |
| (39,391) | 21,109 | (32,623) | ||||||
Income tax (expense) benefit |
| (3,003) |
| 9,106 | (7,874) | 6,395 | ||||||
Net income (loss) | $ | 5,389 | $ | (30,285) | $ | 13,235 | $ | (26,228) | ||||
Earnings (loss) per share: |
|
|
|
| ||||||||
Basic | $ | 0.05 | $ | (0.30) | $ | 0.13 | $ | (0.26) | ||||
Diluted | $ | 0.05 | $ | (0.30) | $ | 0.13 | $ | (0.26) | ||||
Weighted average shares outstanding: |
|
| ||||||||||
Basic |
| 101,265,446 |
| 100,897,815 | 101,225,835 | 100,895,181 | ||||||
Diluted |
| 103,271,838 |
| 100,897,815 | 102,389,768 | 100,895,181 |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
4
Sovos Brands, Inc.
Condensed Consolidated Statements of Comprehensive Income (Loss)
(Unaudited, dollars in thousands)
13 Weeks Ended | 26 Weeks Ended | |||||||||||
| July 1, 2023 |
| June 25, 2022 |
| July 1, 2023 | June 25, 2022 | ||||||
Net income (loss) | $ | 5,389 | $ | (30,285) | $ | 13,235 | $ | (26,228) | ||||
Other comprehensive income: | ||||||||||||
Change in net unrealized gain on derivative instruments | 1,238 | — | 689 | — | ||||||||
Income tax effect | (301) | — | (168) | — | ||||||||
Unrealized gain on derivative instruments, net of tax | 937 | — | 521 | — | ||||||||
Total comprehensive income (loss) | $ | 6,326 | $ | (30,285) | $ | 13,756 | $ | (26,228) |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
5
Sovos Brands, Inc.
Condensed Consolidated Statements of Changes in Stockholders’ Equity
(Unaudited, dollars in thousands, except share data)
|
|
| Additional |
| Retained Earnings |
| Accumulated Other |
| Total | ||||||||
Common Stock | Paid-in | (Accumulated | Comprehensive |
| Stockholders’ | ||||||||||||
Shares | Amount | Capital | Deficit) | Income | Equity | ||||||||||||
Balance at April 1, 2023 |
| 101,226,478 | $ | 101 | $ | 583,172 | $ | (95,445) | $ | 1,133 | $ | 488,961 | |||||
Equity-based compensation expense | — | — | 6,419 | — | — | 6,419 | |||||||||||
Shares issued upon vesting of restricted stock units | 91,767 | — | — | — | — | — | |||||||||||
Other comprehensive income | — | — | — | — | 937 | 937 | |||||||||||
Net income |
| — |
| — |
| — |
| 5,389 | — |
| 5,389 | ||||||
Balance at July 1, 2023 |
| 101,318,245 | $ | 101 | $ | 589,591 | $ | (90,056) | $ | 2,070 | $ | 501,706 |
|
|
| Additional |
| Retained Earnings |
| Accumulated Other |
| Total | ||||||||
Common Stock | Paid-in | (Accumulated | Comprehensive | Stockholders’ | |||||||||||||
Shares | Amount | Capital | Deficit) | Income | Equity | ||||||||||||
Balance at December 31, 2022 |
| 100,967,910 | $ | 101 | $ | 577,664 | $ | (103,291) | $ | 1,549 | $ | 476,023 | |||||
Equity-based compensation expense |
| — |
| — |
| 11,927 |
| — | — |
| 11,927 | ||||||
Shares issued upon vesting of restricted stock units | 350,335 | — | — | — | — | — | |||||||||||
Other comprehensive income | — | — | — | — | 521 | 521 | |||||||||||
Net income | — | — | — | 13,235 | — | 13,235 | |||||||||||
Balance at July 1, 2023 |
| 101,318,245 | $ | 101 | $ | 589,591 | $ | (90,056) | $ | 2,070 | $ | 501,706 |
|
|
| Additional |
| Retained Earnings |
| Accumulated Other |
| Total | ||||||||
Common Stock | Paid-in | (Accumulated | Comprehensive | Stockholders’ | |||||||||||||
Shares | Amount | Capital | Deficit) | Income | Equity | ||||||||||||
Balance at March 26, 2022 |
| 100,892,547 | $ | 101 | $ | 563,313 | $ | (45,783) | $ | — | $ | 517,631 | |||||
Equity-based compensation expense |
| — |
| — |
| 4,547 |
| — | — |
| 4,547 | ||||||
Shares issued upon vesting of restricted stock units | 19,476 | — | — | — | — | — | |||||||||||
Net loss |
| — |
| — |
| — |
| (30,285) | — |
| (30,285) | ||||||
Balance at June 25, 2022 |
| 100,912,023 | $ | 101 | $ | 567,860 | $ | (76,068) | $ | — | $ | 491,893 |
|
|
| Additional |
| Retained Earnings |
| Accumulated Other |
| Total | ||||||||
Common Stock | Paid-in | (Accumulated | Comprehensive | Stockholders’ | |||||||||||||
Shares | Amount | Capital | Deficit) | Income | Equity | ||||||||||||
Balance at December 25, 2021 |
| 100,892,547 | $ | 101 | $ | 559,226 | $ | (49,840) | $ | — | $ | 509,487 | |||||
Equity-based compensation expense |
| — |
| — |
| 8,634 |
| — | — |
| 8,634 | ||||||
Shares issued upon vesting of restricted stock units |
| 19,476 |
| — |
| — |
| — | — |
| — | ||||||
Net loss |
| — |
| — |
| — |
| (26,228) | — |
| (26,228) | ||||||
Balance at June 25, 2022 |
| 100,912,023 | $ | 101 | $ | 567,860 | $ | (76,068) | $ | — | $ | 491,893 |
See accompanying notes to the unaudited condensed consolidated financial statements.
6
Sovos Brands, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited, dollars in thousands)
26 Weeks Ended | ||||||
| July 1, 2023 |
| June 25, 2022 | |||
Operating activities |
|
|
|
| ||
Net income (loss) | $ | 13,235 | $ | (26,228) | ||
Adjustments to reconcile net income (loss) to net cash provided by operating activities: |
|
|
| |||
Depreciation and amortization |
| 17,033 |
| 19,380 | ||
Equity-based compensation expense |
| 11,927 |
| 8,634 | ||
Loss on foreign currency contracts | 198 | 497 | ||||
Non-cash interest expense | 390 | — | ||||
Deferred income taxes |
| (1,309) |
| (10,701) | ||
Amortization of debt issuance costs |
| 633 |
| 633 | ||
Non-cash operating lease expense |
| 1,225 |
| 1,216 | ||
Provision for excess and obsolete inventory | 1,885 | 224 | ||||
Impairment of goodwill | — | 42,052 | ||||
Other |
| — |
| (6) | ||
Changes in operating assets and liabilities: |
|
|
| |||
Accounts receivable, net |
| 19,804 |
| (3,171) | ||
Inventories, net |
| (16,835) |
| (25,234) | ||
Prepaid expenses and other current assets |
| (1,272) |
| 2,077 | ||
Other long-term assets |
| (55) |
| (30) | ||
Accounts payable |
| (2,067) |
| 12,405 | ||
Accrued expenses |
| (8,656) |
| (3,864) | ||
Other long-term liabilities |
| 68 |
| 20 | ||
Operating lease liabilities | (1,621) | (1,630) | ||||
Net cash provided by operating activities |
| 34,583 |
| 16,274 | ||
Investing activities |
|
|
|
| ||
Purchases of property and equipment |
| (3,571) |
| (9,730) | ||
Net cash (used in) investing activities |
| (3,571) |
| (9,730) | ||
Financing activities |
|
|
|
| ||
Repayments of capital lease obligations |
| (41) |
| (47) | ||
Net cash (used in) financing activities |
| (41) |
| (47) | ||
Cash and cash equivalents | ||||||
Net increase in cash and cash equivalents |
| 30,971 |
| 6,497 | ||
Cash and cash equivalents at beginning of period |
| 138,654 |
| 66,154 | ||
Cash and cash equivalents at end of period | $ | 169,625 | $ | 72,651 |
Supplemental disclosures of cash flow information |
|
|
|
| ||
Cash paid for interest | $ | 19,853 |
| $ | 11,350 | |
Cash proceeds from interest | (3,510) | (43) | ||||
Cash paid for taxes |
| 2,789 |
| 3,670 | ||
Proceeds from income tax refunds |
| (43) |
| (11) | ||
Non-cash investing and financing transactions |
|
|
| |||
Lease liabilities arising from operating lease right-of-use assets recognized after ASU No. 2016-02 transition | $ | — | $ | 41 | ||
Acquisition of property and equipment not yet paid | 455 | 100 |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
7
Notes to Unaudited Condensed Consolidated Financial Statements
Note 1. Company Overview
Description of Business
Sovos Brands, Inc. and its wholly-owned subsidiaries (the “Company,” “Sovos Brands,” “we,” “us,” “our”) is a growth-oriented consumer-packaged food company with a portfolio of brands aimed at bringing today’s consumers great tasting food that fits the way they live. The Company’s four wholly-owned operating subsidiaries include: Rao’s Specialty Foods, Inc. (“Rao’s”); Bottom Line Food Processors, Inc. doing business as Michael Angelo’s Gourmet Foods, Inc. (“Michael Angelo’s”); Noosa Yoghurt, LLC (“Noosa”); and Aidaca, LLC. The Company’s principal products include a variety of pasta sauces, dry pasta, soups, frozen entrées, frozen pizza and yogurts, which are primarily sold in the United States. The Company sells products marketed under the brand names Rao’s, Michael Angelo’s, and noosa which are built with authenticity at their core, providing consumers food experiences that are genuine, delicious, and unforgettable. Our products are premium and made with simple, high-quality ingredients. We are focused on continuing to build an organization with the capabilities to acquire and grow brands. We strive to empower our teams to lead with courage and tenacity, with the goal of providing them with the confidence and agility to connect with our consumers and retail partners to drive unparalleled growth. We believe our focus on “one-of-a-kind” brands, products that people love, and passion for our people makes Sovos Brands a “one-of-a-kind” company and enables us to deliver on our objective of creating a growing and sustainable food enterprise yielding financial growth ahead of industry peers.
Through the end of fiscal 2022, the Company sold products marketed under the brand name of Birch Benders, including pancake and waffle mixes, other baking mixes and frozen waffles. See Note 3. Loss on Asset Sale for additional information on the December 30, 2022 divestiture of the Birch Benders brand and certain related assets.
Basis of Presentation
The condensed consolidated financial statements include the accounts of the Company and its subsidiaries and have been prepared in conformity with United States Generally Accepted Accounting Principles (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (the “SEC”). All intercompany balances and transactions have been eliminated. The condensed consolidated financial statements are presented in U.S. dollars.
The Company maintains its accounting records on a 52/53-week fiscal year, ending on the last Saturday in December of each year. Our fiscal year ending December 30, 2023 (“fiscal 2023”) has 52 weeks. Our fiscal year ended December 31, 2022 (“fiscal 2022”) had 53 weeks.
Unaudited Interim Condensed Consolidated Financial Statements
The interim condensed consolidated financial statements and related notes of the Company and its subsidiaries are unaudited. The unaudited interim condensed consolidated financial statements reflect all adjustments and disclosures which are, in our opinion, necessary for a fair presentation of the results of operations, financial position and cash flows for the indicated periods. All such adjustments were of a normal and recurring nature. The year-end balance sheet data was derived from the audited financial statements and, in accordance with the instructions to Form 10-Q, certain information and footnote disclosures required by GAAP have been condensed or omitted. The results reported in these unaudited interim condensed consolidated financial statements are not necessarily indicative of the results that may be reported for the entire fiscal year and should be read in conjunction with our consolidated financial statements for the fiscal year ended December 31, 2022, included in our Annual Report on Form 10-K, filed with the SEC on March 8, 2023 (“2022 Form 10-K”).
Note 2. Summary of Significant Accounting Policies
There have been no material changes in the Company’s significant accounting policies as compared to the significant accounting policies described in Note 2. Summary of Significant Accounting Policies, to the consolidated financial statements included in the Company’s 2022 Form 10-K, other than what is described below.
8
New Accounting Pronouncements and Policies
In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The amendments of ASU No. 2020-04 apply only to contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform and provide optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. During the third quarter of fiscal 2022 the Company elected to apply the hedge accounting expedients related to probability of forecasted transactions to assert probability of the hedged interest payments regardless of the expectation to transition away from LIBOR interest payments and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. During June 2023, the Company elected to apply the relevant hedge accounting expedients related to the change in critical terms of the hedged transactions and hedging instrument, and the change in hedged risk to avoid de-designating the hedging relationship. The Company also applied relevant expedients in paragraph 848-20-35-4 of Topic 848 to avoid reassessing previous accounting determinations that would otherwise be reassessed due to the modification of the hedging instrument. These elections will become effective during the third quarter of fiscal 2023 and the Company does not anticipate the elected expedients to have a material impact to its consolidated financial statements or derivative contracts.
No other new accounting pronouncements issued or effective during the quarter had or is expected to have a material impact on the Company’s consolidated financial statements.
Note 3. Loss on Asset Sale
On December 30, 2022, the Company completed the divestiture of the Birch Benders brand and certain related assets to Hometown Food Company, a portfolio company controlled by Brynwood Partners VIII L.P. The Company operated under a Transition Services Agreement with the buyer through June 30, 2023, and is in the process of winding down the remaining assets and liabilities that were not part of the sale.
The divestiture of the Birch Benders brand and certain related assets positions the Company to focus on its core brands and drive sustainable growth.
For the fiscal year ended December 31, 2022, the Company recognized a pre-tax loss on the sale of Birch Benders of $51.3 million, calculated as follows:
(In thousands) | |||
Cash received | $ | 40,000 | |
Assets sold: |
| ||
Inventory |
| (5,424) | |
Intangible assets, net | (85,867) | ||
Total assets sold |
| (91,291) | |
Loss on asset sale | $ | (51,291) |
9
Note 4. Revenue Recognition
Revenue disaggregated by brand is as follows:
13 Weeks Ended | 26 Weeks Ended | |||||||||||
(In thousands) |
| July 1, 2023 |
| June 25, 2022 |
| July 1, 2023 |
| June 25, 2022 | ||||
Rao’s | $ | 154,888 | $ | 119,798 | $ | 344,079 | $ | 257,210 | ||||
Noosa |
| 47,986 |
| 47,548 |
| 93,270 |
| 89,399 | ||||
Michael Angelo’s |
| 15,123 |
| 19,740 |
| 34,225 |
| 39,982 | ||||
Birch Benders |
| (362) |
| 10,347 |
| (1,148) |
| 20,775 | ||||
Total net sales | $ | 217,635 | $ | 197,433 | $ | 470,426 | $ | 407,366 |
The activity for Birch Benders for the 13 weeks and 26 weeks ended July 1, 2023 is related to winding down promotional discount activity in the period.
Note 5. Inventories, Net
Inventories, net consisted of the following:
(In thousands) |
| July 1, 2023 |
| December 31, 2022 | ||
Finished goods | $ | 94,134 | $ | 76,404 | ||
Raw materials and packaging supplies |
| 13,419 |
| 16,198 | ||
Total inventories, net | $ | 107,553 | $ | 92,602 |
Note 6. Goodwill
There were no changes in the carrying value or impairment charges related to goodwill during the 13 weeks or 26 weeks ended July 1, 2023.
For the 13 weeks ended June 25, 2022, the Company identified the underperformance of the Birch Benders reporting unit as an indicator that required a quantitative assessment to be performed. The Company compared the estimated fair value of the Birch Benders reporting unit to the carrying value of its assets and liabilities, including goodwill. The fair value was established using generally accepted valuation methodologies, including discounted cash flow analysis and comparable public company analysis, both methods weighted equally. As a result, the Company recorded an impairment charge for the full amount of goodwill, $42.1 million, for the 13 weeks ended June 25, 2022.
Note 7. Intangible Assets, Net
Intangible asset, net, consisted of the following:
July 1, 2023 | |||||||||
Gross carrying | Accumulated | Net carrying | |||||||
(In thousands) | amount | amortization | amount | ||||||
Intangible assets - definite lives |
|
|
|
| |||||
Customer relationships | $ | 207,300 | $ | 97,374 | $ | 109,926 | |||
Tradename |
| 101,747 |
| 24,338 |
| 77,409 | |||
309,047 | 121,712 | 187,335 | |||||||
Intangible assets - indefinite lives |
|
|
|
|
| ||||
Tradename | 153,000 | — | 153,000 | ||||||
Total intangible assets | $ | 462,047 | $ | 121,712 | $ | 340,335 |
10
December 31, 2022 | ||||||||||||
Gross carrying | Accumulated | Sale of | Net carrying | |||||||||
(In thousands) |
| amount |
| amortization | intangible assets |
| amount | |||||
Intangible assets - definite lives |
|
|
|
|
| |||||||
Customer relationships | $ | 213,000 | $ | 89,201 | $ | 5,082 | $ | 118,717 | ||||
Tradename |
| 192,347 |
| 31,732 |
| 80,785 |
| 79,830 | ||||
405,347 | 120,933 | 85,867 | 198,547 | |||||||||
Intangible assets - indefinite lives |
|
| ||||||||||
Tradename |
| 153,000 | — | — | 153,000 | |||||||
Total intangible assets | $ | 558,347 | $ | 120,933 | $ | 85,867 | $ | 351,547 |
In connection with the divestiture of the Birch Benders brand and certain related assets, the Company sold the net amount of definite lived tradename and customer relationships in the amounts of $80.8 million and $5.1 million, respectively, for the fiscal year ended December 31, 2022. See Note 3. Loss on Asset Sale for additional discussion. There were no sales of definite lived intangible assets for the 13 weeks or 26 weeks ended July 1, 2023.
Amortization expense related to intangible assets during the 13 weeks ended July 1, 2023 and June 25, 2022 was $5.6 million and $6.8 million, respectively. Amortization expense related to intangible assets during the 26 weeks ended July 1, 2023 and June 25, 2022 was $11.2 million and $13.6 million, respectively.
There were no impairment charges related to intangible assets during the 13 weeks or 26 weeks ended July 1, 2023.
Estimated total intangible amortization expense during the next five fiscal years and thereafter is as follows:
(In thousands) |
| Amortization | |
Remainder of 2023 | $ | 11,213 | |
2024 |
| 22,425 | |
2025 |
| 22,425 | |
2026 |
| 22,425 | |
2027 |
| 17,782 | |
Thereafter |
| 91,065 | |
Total | $ | 187,335 |
Note 8. Accrued Expenses
Accrued expenses consisted of the following:
(In thousands) |
| July 1, 2023 |
| December 31, 2022 | ||
Accrued trade | $ | 22,768 | $ | 32,337 | ||
Accrued general expense |
| 19,104 |
| 17,911 | ||
Accrued compensation and benefits |
| 11,824 |
| 17,328 | ||
Accrued marketing |
| 1,771 |
| 1,995 | ||
Total accrued expenses | $ | 55,467 | $ | 69,571 |
11
Note 9. Long-Term Debt
Long-term debt consisted of the following:
July 1, 2023 | |||||||||
Unamortized | |||||||||
debt issuance | |||||||||
(In thousands) | Principal | costs | Total debt, net | ||||||
Initial First Lien Term Loan Facility |
| $ | 480,800 |
| $ | (4,872) |
| $ | 475,928 |
6,976 |
| 6,976 | |||||||
Total debt | $ | 487,776 | $ | (4,872) | 482,904 | ||||
Less: current portion of finance lease liabilities |
| 80 | |||||||
Total long-term debt |
|
| $ | 482,824 |
December 31, 2022 | |||||||||
| Unamortized | ||||||||
debt issuance | |||||||||
(In thousands) | Principal | costs | Total debt, net | ||||||
Initial First Lien Term Loan Facility | $ | 480,800 | $ | (5,374) | $ | 475,426 | |||
| 7,017 |
| — |
| 7,017 | ||||
Total debt | $ | 487,817 | $ | (5,374) |
| 482,443 | |||
Less: current portion of finance lease liabilities |
|
|
|
| 99 | ||||
Total long-term debt |
|
|
|
| $ | 482,344 |
Senior Debt
In June 2021, Sovos Brands Intermediate, Inc. (“Sovos Intermediate”) entered into a First Lien Credit Agreement (“First Lien Credit Agreement”) among Sovos Intermediate, Sovos Brands Holdings, Inc., Credit Suisse AG, Cayman Islands Branch (“Credit Suisse”), as administrative agent and collateral agent, and the lenders and issuing banks from time to time party thereto (“First Lien Lenders”), consisting of an initial term loan facility of $580.0 million (“Initial First Lien Term Loan Facility”), and a revolving credit facility of $125.0 million (“Revolving Facility”), including a letter of credit facility with a $45.0 million sublimit.
The Initial First Lien Term Loan Facility was issued with a discount of $1.5 million and the Company paid debt issuance costs of $6.8 million. The discounts and debt issuance costs paid on the Initial First Lien Term Loan Facility were capitalized. The debt transaction on the Revolving Facility was accounted for as a debt modification. The Company continued to amortize $0.2 million of debt issuance costs on a previous Revolving Line of Credit over the new life of the debt, and paid $1.1 million in debt issuance costs for the new Revolving Facility, which was capitalized.
In 2021, the Company prepaid $99.2 million of the outstanding principal balance under the Initial First Lien Term Loan Facility. Upon the partial prepayment of the Initial First Lien Term Loan Facility, the Company recognized a $1.4 million proportional loss on the partial extinguishment of the related unamortized issuance costs and discounts. The remaining principal balance on the Initial First Lien Term Loan Facility, after the $99.2 million prepayment, is $480.8 million. The Company has directed Credit Suisse to apply the prepayment against future scheduled principal installments, which eliminates all future principal payments for the remaining term of the loan.
The amortization of debt issuance costs and discount of $0.3 million and $0.3 million for the 13 weeks ended July 1, 2023 and June 25, 2022, respectively, and $0.6 and $0.6 million for the 26 weeks ended July 1, 2023 and June 25, 2022, respectively, is included within interest expense, net in the Condensed Consolidated Statements of Operations.
On June 28, 2023, Sovos Intermediate amended the First Lien Credit Agreement. Going forward, the amended First Lien Credit Agreement (“Amended First Lien Credit Agreement”) replaces the London Inter-Bank Offered Rate (“LIBO
12
Rate”) for loans denominated in dollars with a successor rate based on Term Secured Overnight Financing Rate (“Term SOFR”).
The interest rate for the Initial First Lien Term Loan Facility and Revolving Facility is LIBO Rate (the “base rate”) plus an applicable rate contingent on the Company’s calculated first lien leverage ratio, ranging from 400 to 425 basis points, and was subject to a 50 basis points reduction, at each level, after the consummation of its initial public offering ("IPO"). In no event shall LIBO Rate be less than 0.75% per annum for the Initial First Lien Term Loan Facility or less than 0.00% per annum for the Revolving Line of Credit. As of June 28, 2023, Term SOFR replaced the LIBO Rate as the base rate for loans denominated in dollars. However, to the extent any LIBO Rate loan denominated in dollars was outstanding on June 28, 2023, such loan shall continue to bear interest at the LIBO Rate until the end of the current interest period or payment period applicable to such loan and such loan shall be governed by the terms of First Lien Credit Agreement applicable to LIBO Rate loans denominated in dollars until the earlier of (i) the repayment of such loans or (ii) the conversion of such loans into Term SOFR loans or ABR loans. Effective as of June 28, 2023, a credit spread adjustment (0.11448% per annum for one month tenor, 0.26161% per annum for a three month tenor, 0.42826% per annum for a six month tenor and 0.71513% per annum for a twelve month tenor) shall apply to Term SOFR loans pursuant to the Amended First Lien Credit Agreement.
The Initial First Lien Term Loan Facility matures on June 8, 2028 and the Revolving Facility matures on June 8, 2026. The Initial First Lien Term Loan Facility is collateralized by substantially all the assets of the Company. On December 30, 2022, Sovos Intermediate and Birch Benders, LLC, a Delaware limited liability company (renamed Aidaca, LLC), sold the Birch Benders brand and certain related assets to Hometown Food Company, a Delaware corporation, as permitted under the terms of the First Lien Credit Agreement.
The Company had available credit of $125.0 million under the Revolving Facility as of July 1, 2023 and December 31, 2022, respectively. There was zero outstanding on the Revolving Facility as of July 1, 2023 and December 31, 2022. As of July 1, 2023 and December 31, 2022, the effective interest rate for the Initial First Lien Term Loan Facility and Revolving Facility was 8.77% and 7.91%, respectively.
Loan Covenants
In connection with the Amended First Lien Credit Agreement, the Company has various financial, affirmative and negative covenants that it must adhere to as specified within the loan agreement. The Amended First Lien Credit Agreement contains a springing financial covenant, which requires the Borrower to maintain a first lien net leverage ratio of consolidated first lien net debt to consolidated EBITDA (with certain adjustments as set forth in the Amended First Lien Credit Agreement) no greater than 6.95:1.00. Such financial covenant is tested only if outstanding revolving loans (excluding any undrawn letters of credit) minus unrestricted cash exceed 35% of the aggregate revolving credit commitments. The financial covenant is subject to customary “equity cure” rights. In addition, under the Amended First Lien Credit Agreement, an annual excess cashflow calculation is required, to determine if any excess is required to be paid on the Initial First Lien Term Loan Facility. As of July 1, 2023, the Company had no outstanding revolving loans, so did not meet the requirement to test the financial covenant under the Amended First Lien Credit Agreement.
See Note 10. Leases and Note 17. Related Party Transactions for additional discussion of the finance lease liabilities.
Note 10. Leases
The Company leases real estate in the form of distribution centers, manufacturing facilities, equipment and office space. Generally, the term for real estate leases ranges from 2 to 10 years at inception of the contract. Generally, the term for equipment leases is 5 years at inception of the contract. Most manufacturing facilities and office space leases include one or more options to renew, with renewal terms that generally can extend the lease term from 2 to 30 years. The exercise of lease renewal options is at the Company’s discretion.
Operating and finance lease costs are included within Cost of sales and Selling, general and administrative expenses in the Condensed Consolidated Statements of Operations. Sublease income was not material for the periods presented.
13
The components of lease expense were as follows:
13 Weeks Ended | 26 Weeks Ended | |||||||||||||
(In thousands) | Statement of Operations Caption | July 1, 2023 | June 25, 2022 | July 1, 2023 | June 25, 2022 | |||||||||
Operating lease cost: |
|
|
|
|
|
| ||||||||
Lease cost |
| Cost of sales and Selling, general and administrative | $ | 810 | $ | 839 | $ | 1,621 | $ | 1,679 | ||||
Variable lease cost (1) |
| Cost of sales and Selling, general and administrative |
| 5,331 | 357 |
| 5,758 |
| 720 | |||||
Total operating lease cost |
|
| 6,141 | 1,196 |
| 7,379 |
| 2,399 | ||||||
Short term lease cost |
| Cost of sales and Selling, general and administrative |
| 74 | 50 |
| 109 |
| 96 | |||||
Finance lease cost: |
|
|
|
|
| |||||||||
Amortization of right-of-use assets |
| Cost of sales and Selling, general and administrative |
| 65 | 65 |
| 130 |
| 130 | |||||
Interest on lease liabilities |
| Interest expense, net |
| 132 | 132 |
| 264 |
| 265 | |||||
Total finance lease cost |
|
| 197 | 197 |
| 394 |
| 395 | ||||||
Total lease cost | $ | 6,412 | $ | 1,443 | $ | 7,882 | $ | 2,890 |
(1) | Variable lease cost primarily consists of the cost of inventory sold under a manufacturing and supply agreement, as well as common area maintenance, utilities, taxes and insurance. |
The gross amount of assets and liabilities related to both operating and finance leases were as follows:
(In thousands) | Balance Sheet Caption | July 1, 2023 | December 31, 2022 | |||||
Assets |
|
|
|
|
|
| ||
Operating lease right-of-use assets |
| Operating lease right-of-use assets | $ | 12,107 | $ | 13,332 | ||
Finance lease right-of-use assets |
|
| 5,908 |
| 6,038 | |||
Total lease assets |
| $ | 18,015 | $ | 19,370 | |||
Liabilities |
|
|
|
|
|
| ||
Current: | ||||||||
Operating lease liabilities | Current portion of long-term operating lease liabilities | $ | 3,205 | $ | 3,308 | |||
Finance lease liabilities | Current portion of long-term debt | 80 | 99 | |||||
Long-term: | ||||||||
Operating lease liabilities |
| Long-term operating lease liabilities |
| 12,545 |
| 14,063 | ||
Finance lease liabilities |
|
| 6,896 |
| 6,918 | |||
Total lease liabilities |
| $ | 22,726 | $ | 24,388 |
14
The weighted-average remaining lease term and weighted-average discount rate for operating and finance leases were as follows:
| July 1, 2023 |
| December 31, 2022 | |||
Weighted-average remaining lease term (in years): |
| |||||
Operating leases | 6.1 | 6.4 | ||||
Finance leases | 33.9 | 34.2 | ||||
Weighted-average discount rate | ||||||
Operating leases | 5.0 | % | 4.9 | % | ||
Finance leases |
| 7.9 | % | 7.8 | % |
Future maturities of lease liabilities as of July 1, 2023, were as follows:
(In thousands) |
| Operating Leases |
| Finance Leases | ||
Fiscal year ending: |
|
|
|
| ||
Remainder of 2023 | $ | 2,045 | $ | 305 | ||
2024 |
| 3,493 |
| 557 | ||
2025 |
| 2,982 |
| 549 | ||
2026 |
| 3,005 |
| 520 | ||
2027 |
| 3,064 |
| 525 | ||
Thereafter |
| 3,856 |
| 18,445 | ||
Total lease payments |
| 18,445 |
| 20,901 | ||
Less: Interest |
| (2,695) |
| (13,925) | ||
Present value of lease liabilities | $ | 15,750 | $ | 6,976 |
As of July 1, 2023, the Company did not have any significant additional operating or finance leases that have not yet commenced.
Supplemental cash flow and other information related to leases were as follows:
| 26 Weeks Ended | |||||
(In thousands) | July 1, 2023 | June 25, 2022 | ||||
Cash paid for amounts included in the measurement of lease liabilities |
|
|
|
| ||
Operating cash flows from operating leases | $ | 2,016 | $ | 2,030 | ||
Operating cash flows from finance leases |
| 264 |
| 265 | ||
Financing cash flows from finance leases | 41 | 47 | ||||
Right-of-use assets obtained in exchange for new lease liabilities | ||||||
Finance leases | — | — | ||||
Operating leases | — | 41 |
Note 11. Commitments and Contingencies
Litigation
From time to time, we are subject to various legal actions arising in the ordinary course of our business. We cannot predict with reasonable assurance the outcome of these legal actions brought against us as they are subject to uncertainties. Accordingly, any settlement or resolution in these legal actions may occur and affect our net income (loss) in such period as the settlement or resolution. We do not believe the outcome of any existing legal actions would have a material adverse effect on our consolidated financial statements taken as a whole.
Purchase Commitments
The Company has third-party purchase obligations for raw materials, packaging, and co-manufacturing. These commitments have been entered into based on future projected needs. As of July 1, 2023, the Company had outstanding
15
minimum purchase commitments with three suppliers. The estimated annual minimum purchase commitments with the suppliers are as follows:
Fiscal Year Ending |
| (In thousands) | |
Remainder of 2023 | $ | 1,709 | |
2024 |
| 4,288 | |
2025 |
| 723 | |
2026 |
| — | |
2027 |
| — | |
Thereafter |
| — | |
Total | $ | 6,720 |
See Note 17. Related Party Transactions for information about our commitments to related parties.
Note 12. Fair Value of Financial Instruments
ASC 820, Fair Value Measurements and Disclosures (“ASC 820”), defines fair value as the price that would be received for an asset, or paid to transfer a liability, in an orderly transaction between market participants on the measurement date, and establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value as follows:
Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities;
Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and
Level 3: inputs for the asset or liability that are based on unobservable inputs in which there is little or no market data.
Cash and cash equivalents, current assets and current liabilities
Cash and cash equivalents, accounts receivable, prepaid expenses, accounts payable and accrued expenses are reflected in the Condensed Consolidated Balance Sheets at carrying value, which approximates fair value due to the short-term nature of these instruments.
Borrowing instruments
The Company’s borrowing instruments are recorded at their carrying values in the Condensed Consolidated Balance Sheets, which may differ from their respective fair values. The carrying values and estimated fair values of the Company’s Initial First Lien Term Loan Facility and Revolving Facility approximate their carrying values as of July 1, 2023 and December 31, 2022, based on interest rates currently available to the Company for similar borrowings.
Derivative financial instruments
The Company uses option contracts to manage foreign currency risk and uses interest rate caps (options) to manage interest rate risk. The Company’s derivative assets and liabilities are carried at fair value as required by GAAP. The estimated fair values of the derivative assets and liabilities on the Company’s forward contracts is based on foreign currency exchange rates in active markets. The estimated fair value of the interest rate instruments is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities.
16
To comply with the provisions of ASC 820, we incorporate credit valuation adjustments to appropriately reflect both our own nonperformance risk and the respective counterparty’s nonperformance risk in the fair value measurements. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as collateral postings, thresholds, mutual puts and guarantees.
Although we have determined that the majority of the inputs used to value our derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with our derivatives utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by us and our counterparties. We have determined that the significance of the impact of the credit valuation adjustments made to our derivative contracts, which determination was based on the fair value of each individual contract, was not significant to the overall valuation. As a result, all of our derivatives held as of July 1, 2023 and December 31, 2022 were classified as Level 2 of the fair value hierarchy.
The tables below present the Company’s assets and liabilities measured at fair value on a recurring basis aggregated by the level in the fair value hierarchy within which those measurements fall.
As of July 1, 2023 | Fair Value Measurements Using | ||||||||||||
(In thousands) | Quoted Prices in Active Markets for Identical Assets and Liabilities | Significant Other Observable Inputs | Significant Unobservable Inputs | Balance at July 1, 2023 | |||||||||
Assets | |||||||||||||
Derivatives in cash flow hedging relationships | $ | — | $ | 3,927 | $ | — | $ | 3,927 | |||||
Total assets | $ | — | $ | 3,927 | $ | — | $ | 3,927 | |||||
Liabilities | |||||||||||||
$ | — | $ | 231 | $ | — | $ | 231 | ||||||
Total liabilities | $ | — | $ | 231 | $ | — | $ | 231 | |||||
As of December 31, 2022 | Fair Value Measurements Using | ||||||||||||
(In thousands) | Quoted Prices in Active Markets for Identical Assets and Liabilities | Significant Other Observable Inputs | Significant Unobservable Inputs | Balance at December 31, 2022 | |||||||||
Assets | |||||||||||||
Derivatives in cash flow hedging relationships | $ | — | $ | 3,628 | $ | — | $ | 3,628 | |||||
Total assets | $ | — | $ | 3,628 | $ | — | $ | 3,628 | |||||
Liabilities | |||||||||||||
$ | — | $ | 33 | $ | — | $ | 33 | ||||||
Total liabilities | $ | — | $ | 33 | $ | — | $ | 33 |
The fair value estimates presented herein are based on information available to management as of July 1, 2023. These estimates are not necessarily indicative of the amounts we could ultimately realize. See Note 13. Hedging and Derivative Financial Instruments for additional information.
17
Non-financial assets
The Company’s non-financial assets, which primarily consist of property and equipment, right-of-use assets, goodwill and other intangible assets, are not required to be carried at fair value on a recurring basis and are reported at carrying value. The fair values of these assets are determined, as required, based on Level 3 measurements, including estimates of the amount and timing of future cash flows based upon historical experience, expected market conditions, and management’s plans.
There were no transfers of financial instruments between the three levels of fair value hierarchy during the 26 weeks ended July 1, 2023 and the fiscal year ended December 31, 2022.
Note 13. Hedging and Derivative Financial Instruments
The Company is directly and indirectly affected by changes in certain market conditions. These changes in market conditions may adversely impact the Company’s financial performance and are referred to as “market risks.” When deemed appropriate, the Company uses derivatives as a risk management tool to mitigate the potential impact of certain market risks. The primary market risks managed by the Company through the use of derivative instruments are foreign currency exchange rate risk and interest rate risk.
The Company uses various types of derivative instruments including, but not limited to, option contracts, collars and interest rate caps. An option contract is an agreement that conveys the purchaser the right, but not the obligation, to buy or sell a quantity of a currency or commodity at a predetermined rate or price during a period or at a time in the future. A collar is a strategy that uses a combination of options to limit the range of possible positive or negative returns on an underlying asset or liability to a specific range, or to protect expected future cash flows. To do this, an investor simultaneously buys a put option and sells (writes) a call option, or alternatively buys a call option and sells (writes) a put option. An interest rate cap involves the receipt of variable amounts from a counterparty if interest rates rise above the strike rate on the contract in exchange for an up-front premium. We do not enter into derivative financial instruments for trading purposes.
All derivative instruments are carried at fair value in the Condensed Consolidated Balance Sheets, primarily in the following line items, as applicable: prepaid expenses and other current assets, other long-term assets and accrued expenses. The carrying values of the derivatives reflect the impact of netting agreements. These netting agreements allow the Company to net settle positive and negative positions (assets and liabilities) arising from different transactions with the same counterparty.
The accounting for gains and losses that result from changes in the fair values of derivative instruments depends on whether the derivatives have been designated and qualify as hedging instruments and the type of hedging relationships. Derivatives can be designated as fair value hedges, cash flow hedges or economic hedges. The interest rate cap derivative is designated and qualifies as a cash flow hedge. The foreign currency derivative instruments are considered an economic hedge as they do not qualify for hedge accounting treatment.
The Company determines the fair values of its derivatives based on quoted market prices or pricing models using current market rates. The notional amounts of the derivative financial instruments do not necessarily represent amounts exchanged by the parties and, therefore, are not a direct measure of our exposure to the financial risks described above. The amounts exchanged are calculated by reference to the notional amounts and by other terms of the derivatives, such as interest rates or foreign currency exchange rates. The Company does not view the fair values of its derivatives in isolation but rather in relation to the fair values or cash flows of the underlying hedged transactions or other exposures. Virtually all our derivatives are straightforward over-the-counter instruments with liquid markets. See Note 12. Fair Value of Financial Instruments for additional information.
Cash Flow Hedges of Interest Rate Risk
The Company’s objectives in using interest rate derivatives are to add stability to interest expense and manage its exposure to interest rate movements. To accomplish these objectives, the Company primarily uses interest rate caps as part
18
of its interest rate risk management strategy. Interest rate caps designated as cash flow hedges involve the receipt of variable amounts from a counterparty if interest rates rise above the strike rate on the contract in exchange for an up-front premium. During the 13 weeks and 26 weeks ended July 1, 2023, such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt.
For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in other comprehensive income (loss) (“OCI”) in the Condensed Consolidated Statements of Other Comprehensive Income (Loss) and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings. Amounts reported in OCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt. Over the next 12 months, the Company estimates that an additional $2.4 million will be reclassified as a reduction to interest expense.
During the fiscal year ended December 31, 2022, the Company entered into a cash flow hedge to manage interest rate risk on its variable rate debt under the Initial First Lien Term Loan Facility. Through the second quarter of fiscal 2023, the Company had one LIBOR interest rate cap agreement (the “LIBOR Cap Agreement”) with a total hedged notional amount of $240.0 million that was designated as a cash flow hedge of interest rate risk. The LIBOR Cap Agreement has a strike price of 4.00% and a maturity date of July 31, 2024. As of June 28, 2023, in conjunction with the cessation of LIBOR, the floating-rate index on the LIBOR Cap Agreement (now the “SOFR Cap Agreement”) became USD-SOFR Compound plus the applicable ISDA Fallback rate for the tenor (in accordance with the ISDA Fallbacks Protocol), subject to the expiration of the existing tenor. No other critical items were amended. The LIBOR Cap Agreement and the SOFR Cap Agreement are designated for cash flow hedge accounting with all changes in fair value deferred into accumulated OCI.
Within the Company’s Condensed Consolidated Balance Sheets, the interest rate cap is recorded at fair value. The cash flows related to the interest rate caps are classified as operating activities in the Condensed Consolidated Statements of Cash Flows.
Economic (Non-Designated) Hedging Strategy
The Company uses certain derivatives as economic hedges of foreign currency. Although these derivatives did not qualify for hedge accounting, they are effective economic hedges. The Company uses foreign currency economic hedges to offset the earnings impact that fluctuations in foreign currency exchange rates have on certain monetary assets and liabilities denominated in nonfunctional currencies outside of a contractually agreed upon foreign exchange rate range. The total notional values of derivatives related to our foreign currency economic hedges were $332.9 million and $145.7 million as of July 1, 2023 and December 31, 2022, respectively. As of July 1, 2023, the Company’s foreign currency hedges to offset the earnings impact of foreign currency exchange rates extend through May 2024.
The changes in the fair values of economic hedges used to offset those monetary assets and liabilities are immediately recognized in earnings in the selling, general and administrative line item in our Condensed Consolidated Statements of Operations. Within the Company’s Condensed Consolidated Balance Sheets, the foreign currency economic hedges are recorded at fair value. The cash flows related to the foreign currency economic hedges are classified as operating activities in the Condensed Consolidated Statements of Cash Flows.
19
The following table presents the fair values of the Company’s derivative instruments:
| July 1, 2023 | December 31, 2022 | ||||||||||||
(In thousands) | Location |
| Derivative |
| Derivative |
| Derivative |
| Derivative | |||||
Derivatives not designated as hedging instruments under Subtopic 815-20 | ||||||||||||||
Foreign currency contracts(1) | $ | — | $ | 231 | $ | — | $ | 33 | ||||||
Total derivatives not designated as hedging instruments | $ | — | $ | 231 | $ | — | $ | 33 | ||||||
Derivatives designated as hedging instruments under Subtopic 815-20 | ||||||||||||||
Interest rate caps - short term | Prepaid expenses and other current assets | $ | 3,108 | $ | — | $ | 1,997 | $ | — | |||||
Interest rate caps - long term | Other long-term assets | 819 | — | 1,631 | — | |||||||||
Total derivatives designated as hedging instruments | $ | 3,927 | $ | — | $ | 3,628 | $ | — | ||||||
Total derivatives | $ | 3,927 | $ | 231 | $ | 3,628 | $ | 33 |
(1) | Derivative instruments within this category are subject to master netting arrangements and are presented on a net basis in the Condensed Consolidated Balance Sheets in accordance with ASC 210, Balance Sheet, Subtopic 210-20. See tables below showing the effects of offsetting derivative assets and liabilities. |
The following table presents the pre-tax effect of cash flow hedge accounting on accumulated OCI for the periods presented:
(In thousands) | Amount of Gain Recognized in OCI | |||||||||||
13 Weeks Ended | 26 Weeks Ended | |||||||||||
Derivatives in Subtopic 815-20 Hedging Relationships |
| July 1, 2023 |
| June 25, 2022 |
| July 1, 2023 |
| June 25, 2022 | ||||
Derivatives in cash flow hedging relationships | ||||||||||||
Interest rate caps | $ | 1,707 | $ | — | $ | 1,413 | $ | — | ||||
(In thousands) | Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income | |||||||||||
13 Weeks Ended | 26 Weeks Ended | |||||||||||
Location of Gain or (Loss) Reclassified from Accumulated OCI into Income | July 1, 2023 |
| June 25, 2022 |
| July 1, 2023 |
| June 25, 2022 | |||||
Derivatives in cash flow hedging relationships | ||||||||||||
$ | 468 | $ | — | $ | 723 | $ | — |
20
The following table presents the effect of the Company’s derivative financial instruments on the Condensed Consolidated Statements of Operations for the periods presented:
Gain (Loss) Recognized | |||||||||||
13 Weeks Ended | 26 Weeks Ended | ||||||||||
July 1, | June 25, | July 1, | June 25, | ||||||||
(In thousands) |
| Statement of Operations Location |
| 2023 |
| 2022 |
|
| 2023 |
| 2022 |
Total amounts of expense presented in the Statements of Operations in which the derivatives not designated as hedging are recorded | Selling, general and administrative | $ 47,633 | 39,449 | $ 91,047 | 73,364 | ||||||
The effects of derivatives not designated as hedging instruments under Subtopic 815-20: | |||||||||||
Foreign currency contracts | Selling, general and administrative | (331) | (497) | (198) | (497) | ||||||
Total amounts of expense presented in the Statements of Operations in which the derivatives designated as hedging are recorded | Interest expense, net | 8,678 | 5,713 | 17,379 | 11,735 | ||||||
The effects of derivatives designated as hedging instruments under Subtopic 815-20: | |||||||||||
Interest rate caps | Interest expense, net | 468 | — | 723 | — |
The net amounts of derivative assets or liabilities in the tables below can be reconciled to the tabular disclosure of fair value which provides the location that derivative assets and liabilities are presented on the Condensed Consolidated Balance Sheets. The following tables present a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of July 1, 2023 and December 31, 2022.
Offsetting of Derivative Assets | ||||||||||||||||||
As of July 1, 2023 | ||||||||||||||||||
Gross Amounts Not Offset in the Balance Sheet | ||||||||||||||||||
(In thousands) |
| Gross Amounts of Recognized Assets |
| Gross Amounts Offset in the Balance Sheet |
| Net Amounts of Assets Presented in the Balance Sheet |
| Financial Instruments |
| Cash Collateral Posted |
| Net Amount | ||||||
Derivatives | ||||||||||||||||||
Foreign currency contracts | $ | 413 | $ | (413) | $ | — | $ | — | $ | — | $ | — | ||||||
Total derivatives, subject to a master netting arrangement | 413 | (413) | — | — | — | — | ||||||||||||
Total derivatives, not subject to a master netting arrangement | 3,927 | — | 3,927 | — | — | 3,927 | ||||||||||||
Total derivatives | $ | 4,340 | $ | (413) | $ | 3,927 | $ | — | $ | — | $ | 3,927 |
21
Offsetting of Derivative Liabilities | ||||||||||||||||||
As of July 1, 2023 | ||||||||||||||||||
Gross Amounts Not Offset in the Balance Sheet | ||||||||||||||||||
(In thousands) |
| Gross Amounts of Recognized Liabilities |
| Gross Amounts Offset in the Balance Sheet |
| Net Amounts of Liabilities Presented in the Balance Sheet | ' | Financial Instruments |
| Cash Collateral Posted |
| Net Amount | ||||||
Derivatives | ||||||||||||||||||
Foreign currency contracts | $ | (644) | $ | 413 | $ | (231) | $ | — | $ | — | $ | (231) | ||||||
Total derivatives, subject to a master netting arrangement | (644) | 413 | (231) | — | — | (231) | ||||||||||||
Total derivatives, not subject to a master netting arrangement | — | — | — | — | — | — | ||||||||||||
Total derivatives | $ | (644) | $ | 413 | $ | (231) | $ | — | $ | — | $ | (231) |
Offsetting of Derivative Assets | ||||||||||||||||||
As of December 31, 2022 | ||||||||||||||||||
Gross Amounts Not Offset in the Balance Sheet | ||||||||||||||||||
(In thousands) |
| Gross Amounts of Recognized Assets |
| Gross Amounts Offset in the Balance Sheet |
| Net Amounts of Assets Presented in the Balance Sheet |
| Financial Instruments |
| Cash Collateral Posted |
| Net Amount | ||||||
Derivatives | ||||||||||||||||||
Foreign currency contracts | $ | 56 | $ | (56) | $ | — | $ | — | $ | — | $ | — | ||||||
Total derivatives, subject to a master netting arrangement | 56 | (56) | — | — | — | — | ||||||||||||
Total derivatives, not subject to a master netting arrangement | 3,628 | — | 3,628 | — | — | 3,628 | ||||||||||||
Total derivatives | $ | 3,684 | $ | (56) | $ | 3,628 | $ | — | $ | — | $ | 3,628 |
Offsetting of Derivative Liabilities | ||||||||||||||||||
As of December 31, 2022 | ||||||||||||||||||
Gross Amounts Not Offset in the Balance Sheet | ||||||||||||||||||
(In thousands) |
| Gross Amounts of Recognized Liabilities |
| Gross Amounts Offset in the Balance Sheet |
| Net Amounts of Liabilities Presented in the Balance Sheet |
| Financial Instruments |
| Cash Collateral Posted |
| Net Amount | ||||||
Derivatives | ||||||||||||||||||
Foreign currency contracts | $ | (89) | $ | 56 | $ | (33) | $ | — | $ | — | $ | (33) | ||||||
Total derivatives, subject to a master netting arrangement | (89) | 56 | (33) | — | — | (33) | ||||||||||||
Total derivatives, not subject to a master netting arrangement | — | — | — | — | — | — | ||||||||||||
Total derivatives | $ | (89) | $ | 56 | $ | (33) | $ | — | $ | — | $ | (33) |
22
Note 14. Stockholders’ Equity
Common Stock
Prior to the IPO, the Company had a total of 74,058,447 shares issued and .
On September 27, 2021, the Company closed its IPO of 23,334,000 shares of common stock, $0.001 par value per share, at an offering price of $12.00 per share, and received net proceeds from the IPO of approximately $263.2 million, net of $16.8 million in underwriting discounts and commissions.
Subsequent to the IPO, the underwriters exercised their option to purchase an additional 3,500,100 shares of common stock. The Company closed its sale of such additional shares on October 5, 2021, resulting in net proceeds of approximately $39.5 million, net of $2.5 million in underwriting discounts and commissions.
On August 10, 2022, the Company completed a secondary offering, in which certain of its stockholders (the “Selling Stockholders”) sold 8,500,000 shares of common stock in an underwritten public offering at an offering price of $14.00 per share, with all proceeds going to the Selling Stockholders. Subsequent to the secondary offering, the underwriters exercised their option to purchase an additional 1,275,000 shares of common stock, and the sale of such additional shares closed on August 22, 2022, with all proceeds going to the Selling Stockholders.
On May 15, 2023, the Company completed a secondary offering, in which the Selling Stockholders sold 10,000,000 shares of common stock in an underwritten public offering at an offering price of $17.50 per share, with all proceeds going to the Selling Stockholders. Subsequent to the secondary offering, the underwriters exercised their option to purchase an additional 1,500,000 shares of common stock, and the sale of such additional shares closed on May 17, 2023, with all proceeds going to the Selling Stockholders.
Preferred Stock
On September 23, 2021, the Company filed an amended and restated certificate of incorporation (“Amended and Restated Charter”) with the Secretary of State of the State of Delaware, which was effective on September 23, 2021. As a result of the filing of the Amended and Restated Charter, the Company was authorized to issue 510,000,000 shares, divided into two classes as follows: (i) 500,000,000 shares are designated shares of common stock, par value $0.001 per share, and (ii) 10,000,000 shares are designated shares of preferred stock, par value $0.001 per share. There were no shares of preferred stock issued and outstanding as of July 1, 2023 and December 31, 2022.
Note 15. Equity-Based Compensation
2017 Equity Incentive Plan
In 2017, the Sovos Brands Limited Partnership (the “Limited Partnership”) 2017 Equity Incentive Plan (“2017 Plan”) was established providing certain employees and nonemployees of the Company equity-based compensation in the form of Incentive Units (“IUs”) of the Limited Partnership, as consideration for services to the Company. The IUs, were deemed to be equity instruments subject to expense recognition under FASB ASC 718, Compensation — Stock Compensation. The estimate of fair value of the IUs granted was determined as of the grant date.
In connection with the IPO, the Limited Partnership distributed its shares of Sovos Brands, Inc. common stock to its limited partners, including holders of IUs, in accordance with the applicable terms of its partnership agreement.
Holders of IUs received shares of common stock and restricted common stock of Sovos Brands, Inc. in respect of their IUs. The common stock was distributed with respect to vested IUs and the restricted common stock was distributed with respect to nonvested IUs, with the vesting of such restricted common stock tracking the same vesting terms as the related nonvested IUs at the time of distribution.
23
Restricted Common Stock
In connection with the IPO, a change in the vesting of the existing performance-based IUs and accordingly the related distributed restricted stock resulted in a modification to the grants and required the shares to be revalued as of the IPO date, resulting in a modified grant date fair value of approximately $13.0 million. The fair value of the performance-based restricted stock awards was calculated using a Monte Carlo simulation option pricing model which requires the Company to make estimates and assumptions, such as expected volatility, expected term and expected risk-free interest rate. Specifically, the model revalued the performance units based on the revised vesting condition of the x multiple of invested capital (“MOIC”) restricted stock units achieving the x MOIC based on a 30-day volume weighted average price with the remainder of the restricted stock units vesting upon the earlier of the Limited Partnership owning 25% or less of the Company or 30 months post-IPO. On November 3, 2021, the performance condition of the x MOIC restricted common stock was met and, accordingly, 683,442 shares of restricted stock with a performance-based vesting condition vested.
On November 4, 2021, the Company and the Limited Partnership modified a portion of the existing equity-based compensation awards dated September 22, 2021 among the Company, the Limited Partnership and the holders of such restricted stock. As a result of this modification, a portion of the shares that would have vested based upon a The fair value of the modified performance-based restricted stock awards was calculated using a Monte Carlo simulation option pricing model which requires the Company to make estimates and assumptions, such as expected volatility, expected term and expected risk-free interest rate, resulting in an incremental modified grant date fair value of approximately $6.1 million.
x MOIC (including any related linear interpolation, the “Original Vesting Criteria”) instead vest on the last day of fiscal 2022 or on the last day of fiscal 2023, or upon achievement of the Original Vesting Criteria, if earlier.On February 10, 2023, the Company and the Limited Partnership modified a portion of the existing equity-based compensation awards dated September 22, 2021 among the Company, Limited Partnership and the holders of such restricted stock. As a result of these modifications, a portion of the shares that would have vested based upon a MOIC or a MOIC (including any related linear interpolation, the “Original Vesting Criteria”) instead vest 50% on September 23, 2024 and 50% on September 23, 2025, or upon achievement of the Original Vesting Criteria, if earlier. The fair value of the modified performance-based restricted stock awards was calculated using a Monte Carlo simulation option pricing model which requires the Company to make estimates and assumptions, such as expected volatility, expected term and expected risk-free interest rate, resulting in an incremental modified grant date fair value of approximately $5.5 million.
As of July 1, 2023, 3,691 shares of restricted common stock resulting from the distribution of common stock with respect to nonvested time-based IUs will vest upon fulfilling time-based service conditions and are scheduled to vest through July 2024. As of July 1, 2023, there were 1,839,668 shares of restricted common stock resulting from the distribution with respect to nonvested performance-based IUs, of which 169,698 shares will vest on the earlier of December 30, 2023 or when the original performance condition is achieved, 509,210 shares will vest on the earlier of when the original performance condition is achieved or 50% on September 23, 2024 and 50% on September 23, 2025 and the remaining 1,160,760 shares will vest only if certain performance conditions, including exceeding various MOIC levels, are achieved. Shares of restricted common stock that do not vest are not cancelled but instead remain outstanding and are forfeited back to the Limited Partnership.
2021 Equity Incentive Plan
Effective September 21, 2021, the Company adopted the 2021 Equity Incentive Plan (the “2021 Plan”) which reserves 9,739,244 shares of common stock to grant stock options, stock appreciation rights, restricted stock awards, restricted stock units or equity-based awards to eligible employees, consultants and non-employee directors. All 2021 Plan awards, including those described below, are subject in general to the employee’s, consultant’s or non-employee director’s continued service through the vesting date.
Restricted Stock Units
During the 26 weeks ended July 1, 2023, the Company granted 485,730 RSUs to certain employees and non-employee directors. The RSUs included (i) 355,762 RSUs issued to employees with each award vesting in two equal annual installments, (ii) 94,964 RSUs issued to an employee vesting in three equal annual installments, and (iii) 35,004 RSUs
24
issued to non-employee directors that vest on the earlier of the first anniversary of the grant and immediately prior to our 2024 annual meeting of stockholders.
During the 26 weeks ended June 25, 2022, the Company granted 673,415 RSUs to certain employees and non-employee directors. The RSUs included (i) 576,688 RSUs issued to employees with each award vesting in two equal annual installments, (ii) 76,039 RSUs issued to an employee vesting in three equal annual installments, and (iii) 20,688 RSUs issued to non-employee directors that vest on the earlier of the first anniversary of the grant and immediately prior to our 2023 annual meeting of stockholders.
Performance-based Restricted Stock Units
In connection with the IPO and under the 2021 Plan, the Company granted 687,690 performance-based restricted stock units (“PSUs”) to certain employees with each award vesting subject in general to the achievement of the performance condition. The fair value of the PSUs was estimated using a Monte Carlo simulation option pricing model, which requires the Company to make estimates and assumptions, such as expected volatility, expected term and expected risk-free interest rate.
On February 10, 2023, the Company modified the IPO PSUs dated September 23, 2021. As a result of this modification, the shares that would have vested based upon the achievement of a performance condition that measures the Total Shareholder Return (“TSR”) (the “Original Vesting Criteria”) instead vest 50% on September 23, 2024 and 50% on September 23, 2025, or upon achievement of the Original Vesting Criteria, if earlier. The fair value of the modified PSUs was calculated using a Monte Carlo simulation option pricing model which requires the Company to make estimates and assumptions, such as expected volatility, expected term and expected risk-free interest rate, resulting in an incremental modified grant date fair value of approximately $4.3 million.
During the 26 weeks ended July 1, 2023 and June 25, 2022, the Company granted 470,048 PSUs and 343,800 PSUs, respectively, to employees with each award vesting subject in general to the achievement of a performance condition that measures the TSR relative to the TSR of the constituents of a custom peer group (“relative TSR”). The number of shares that may be earned ranges from 0% to 200%, with 100% vesting upon achievement of target performance, with straight-line interpolation applied. The fair value of the PSUs granted during the 26 weeks ended July 1, 2023 was estimated using a Monte Carlo simulation option pricing model, which requires the Company to make estimates and assumptions, such as expected volatility, expected term and expected risk-free interest rate.
As of July 1, 2023, there was an aggregate of 6,257,186 shares of common stock available for future equity awards under the 2021 Plan (treating PSUs that vest based on relative TSR at the 100% target level).
Equity-based Compensation Expense
The Company grants equity-based compensation awards to certain employees, officers and non-employee directors as long-term incentive compensation and recognizes the related expense for these awards ratably over the applicable vesting period. Such expense is recognized as a selling, general and administrative expense in the Condensed Consolidated
25
Statements of Operations. The following table summarizes the equity-based compensation expense recognized for the Company’s equity plans:
| 13 Weeks Ended |
| 26 Weeks Ended | |||||||||
(In thousands) | July 1, 2023 | June 25, 2022 |
| July 1, 2023 | June 25, 2022 | |||||||
Equity awards under the 2017 Plan (Pre-IPO) |
|
|
|
|
|
|
| |||||
RSAs | $ | 135 | $ | 292 | $ | 273 | $ | 648 | ||||
PSAs |
| 1,792 |
| 1,663 |
| 3,399 |
| 3,224 | ||||
Total equity-based compensation expense for the 2017 Plan | 1,927 | 1,955 | 3,672 | 3,872 | ||||||||
Equity awards under the 2021 Plan (Post-IPO) | ||||||||||||
RSUs | 3,456 | 1,787 | 6,342 | 3,267 | ||||||||
PSUs | 1,036 | 805 | 1,913 | 1,495 | ||||||||
Total equity-based compensation expense for the 2021 Plan | 4,492 | 2,592 | 8,255 | 4,762 | ||||||||
Total equity-based compensation expense | $ | 6,419 | $ | 4,547 | $ | 11,927 | $ | 8,634 |
The Company expects to record equity-based compensation expense of approximately $38.8 million through the second quarter of 2026 resulting from the issuance of the RSAs and PSAs under the 2017 Plan and RSUs and PSUs under the 2021 Plan.
Note 16. Income Taxes
The income tax (expense) benefit and the effective tax rate resulting from operations were as follows:
13 Weeks Ended |
| 26 Weeks Ended | ||||||||||||
(In thousands) | July 1, 2023 | June 25, 2022 |
| July 1, 2023 | June 25, 2022 |
| ||||||||
Income (loss) before income taxes |
| $ | 8,392 |
| $ | (39,391) |
| $ | 21,109 |
| $ | (32,623) | ||
Effective income tax (expense) benefit | $ | (3,003) | $ | 9,106 | $ | (7,874) | $ | 6,395 | ||||||
Effective tax rate |
| 35.8 | % |
| 23.1 | % |
| 37.3 | % |
| 19.6 | % |
The effective tax rates for the 13 weeks and 26 weeks ended July 1, 2023 and June 25, 2022 differ from the U.S. federal statutory income tax rate of 21% primarily due to changes in income (loss) before taxes, permanent items including limitation on the deduction of executive compensation for public companies and nondeductible equity-based compensation, state taxes and various discrete items including the impairment of goodwill in 2022.
Note 17. Related Party Transactions
The Company has two related party leases for a manufacturing facility and land. The facility and land are leased from Morning Fresh Dairy (“Morning Fresh”), a related party entity owned and controlled by Robert L. Graves, a former member of the Board of Directors (“Board”) and equity holder of the Company. The facility lease and land lease are classified as a finance lease and operating lease, respectively, based on the original lease term and reasonably certain renewal options. As of July 1, 2023, the facility has a lease liability balance of $6.8 million which is primarily recognized as long-term debt in our Condensed Consolidated Balance Sheets. As of July 1, 2023, the land lease has a liability balance of $0.5 million which is primarily recognized as long-term operating lease liabilities in our Condensed Consolidated Balance Sheets.
The facility and land lease contained total payments of approximately $160 thousand and $143 thousand for the 13 weeks ended July 1, 2023 and June 25, 2022, respectively, and $305 thousand and $285 thousand for the 26 weeks ended July 1, 2023 and June 25, 2022, respectively. In addition, $64 thousand and $45 thousand was paid for the 13 weeks ended July 1, 2023 and June 25, 2022, respectively, and $109 thousand and $91 thousand was paid for the 26 weeks ended July 1, 2023 and June 25, 2022, respectively, for a proportionate share of utilities, taxes and insurance.
Morning Fresh regularly purchases finished goods inventory from the Company for sale to its customers. Additionally, Morning Fresh regularly supplies milk used in the Company’s manufacturing process.
26
Sales to and purchases from Morning Fresh were as follows:
13 Weeks Ended |
| 26 Weeks Ended | ||||||||||
(In thousands) | July 1, 2023 | June 25, 2022 | July 1, 2023 | June 25, 2022 | ||||||||
Sales | $ | 130 | $ | 124 | $ | 243 | $ | 241 | ||||
Purchases | $ | 1,917 | $ | 2,296 | $ | 3,837 | $ | 4,266 |
Amounts outstanding in respect to Morning Fresh transactions were as follows:
(In thousands) |
| July 1, 2023 |
| December 31, 2022 | ||
Receivables | $ | 17 | $ | 29 | ||
Payables | $ | 959 | $ | 870 |
The Company has a milk supply agreement with Morning Fresh (“Milk Supply Agreement”) for a base term ending December 31, 2027, with the option available for extension for a total of fifteen additional
periods to December 31, 2057. Four years’ advance written notice is required to terminate the agreement. Milk will be priced on a month-to-month basis by USDA Central Federal Order No. 32 for Class II milk, plus surcharges and premiums, provided that the final price of the milk shall be 23.24 cents per hundred weight less than the published Dairy Farmers of America bill for that month. The Company will accept up to 3,650,000 gallons as determined by Morning Fresh in 2020, and for each year of the term thereafter. As of July 1, 2023, the Company has future commitments to purchase approximately $35.9 million of milk from Morning Fresh, approximated at current market price. In addition, under the Milk Supply Agreement, the Company has agreed to pay an additional $33 thousand monthly through December 31, 2027 to cover the landowner’s incremental costs relating to capital improvements necessary to support increased milk production required by the Company over the term of this agreement. If the agreement is terminated before December 1, 2027, the Company will be required to pay an early termination penalty, which declines from $3.0 million at the inception of the agreement to $0 over the ten-year term, based on an amortization table outlined in the agreement.As of July 1, 2023, the estimated annual minimum purchase commitments with Morning Fresh are as follows:
Fiscal Year Ending |
| (In thousands) | |
Remainder of 2023 | $ | 4,212 | |
2024 | 8,375 | ||
2025 | 8,375 | ||
2026 | 8,375 | ||
2027 | 8,375 | ||
Thereafter | — | ||
Total | $ | 37,712 |
In May 2023, we entered into a consulting agreement with Mr. Graves. The consulting agreement has a term of three years and stipulates that, in exchange for providing advice and support with respect to water treatment and other operational systems, the Company will pay Mr. Graves $100 thousand per year. Additionally, pursuant to the consulting agreement, in June 2023 the Company granted a one-time RSU equity award to Mr. Graves with a grant date fair value of $100 thousand.
Advent International Corporation (“Advent”) is a private equity firm which has invested funds in our common stock. Advent and its affiliates have ownership interests in a broad range of companies. We have entered and may in the future enter into commercial transactions in the ordinary course of our business with some of these companies, including the sale of goods and services and the purchase of goods and services.
The Company pays legal expenses and tax compliance fees on behalf of the Limited Partnership and carries a balance within other long-term assets that reflects the amount due from the Limited Partnership. As of July 1, 2023 and December 31, 2022, the receivable balance was $0.1 million and $0.1 million, respectively.
27
Note 18. Earnings (Loss) Per Share
Basic earnings per share (“EPS”) is calculated by dividing net income (loss) for the period by the weighted-average number of common shares outstanding for the period without consideration of potential common shares. Diluted EPS is calculated using the weighted average number of common shares outstanding including the dilutive effect of equity awards as determined under the treasury stock method. In periods when the Company has a net loss, equity awards are excluded from the calculation of diluted EPS as their inclusion would have an anti-dilutive effect. The Company reported a net loss for the 13 weeks and 26 weeks ended June 25, 2022, and therefore excluded 423,240 shares and 152,108 shares, respectively, from the calculation of diluted EPS for those periods. The following table presents the computation of EPS for the 13 weeks and 26 weeks ended July 1, 2023 and June 25, 2022.
13 Weeks Ended | 26 Weeks Ended | |||||||||||
(In thousands, except share and per share amounts) |
| July 1, 2023 |
| June 25, 2022 |
| July 1, 2023 |
| June 25, 2022 | ||||
Net income (loss) | $ | 5,389 | $ | (30,285) | $ | 13,235 | $ | (26,228) | ||||
|
|
|
|
|
| |||||||
Weighted average basic common shares outstanding |
| 101,265,446 | 100,897,815 | 101,225,835 | 100,895,181 | |||||||
Effect of dilutive securities: | ||||||||||||
Restricted stock units |
| 1,124,144 |
| — |
| 657,373 |
| — | ||||
Performance stock units |
| 882,248 | — | 506,560 | — | |||||||
Total dilutive securities | 2,006,392 | — | 1,163,933 | — | ||||||||
Weighted average and potential dilutive common shares outstanding | 103,271,838 | 100,897,815 | 102,389,768 | 100,895,181 | ||||||||
Earnings (loss) per share | ||||||||||||
Basic | $ | 0.05 | $ | (0.30) | $ | 0.13 | $ | (0.26) | ||||
Diluted | $ | 0.05 | $ | (0.30) | $ | 0.13 | $ | (0.26) |
For the 13 weeks ended July 1, 2023, 67,594 RSUs and no PSUs were outstanding, but were excluded in the computation of diluted EPS because these RSUs and PSUs were considered to be anti-dilutive based on the result of the treasury stock method calculation for incremental shares. For the 13 weeks ended June 25, 2022, there were no shares considered to be anti-dilutive based on the result of the treasury stock method calculation for incremental shares.
For the 26 weeks ended July 1, 2023, 67,594 RSUs and 429,082 PSUs were outstanding, but were excluded in the computation of diluted EPS because these RSUs and PSUs were considered to be anti-dilutive based on the result of the treasury stock method calculation for incremental shares. For the 26 weeks ended June 25, 2022, there were no shares considered to be anti-dilutive based on the result of the treasury stock method calculation for incremental shares.
Note 19. Subsequent Events
Pending Merger with Campbell Soup Company
On August 7, 2023, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Campbell Soup Company (“Campbell”) and Premium Products Merger Sub, Inc. (“Merger Sub”). Upon the terms and subject to the conditions stated in the Merger Agreement, Merger Sub will merge with and into the Company (the “Merger”), and the Company will become a wholly owned subsidiary of Campbell. The Company’s board of directors (the “Company Board”) and the board of directors of Campbell have approved the Merger Agreement and the transactions described therein.
Pursuant to the Merger Agreement, at the effective time of the Merger (“Effective Time”), each issued and outstanding share of the Company’s common stock (“Company Stock”), except for certain shares of Company Stock specified in the Merger Agreement, will be canceled and automatically converted into the right to receive (i) $23.00 per share, and (ii) if the Merger is not effective by May 7, 2024, an additional $0.00182 per day beginning May 8, 2024, up to but excluding the date the Merger becomes effective.
28
Consummation of the Merger is subject to the satisfaction or waiver of certain customary closing conditions, including, (i) the affirmative vote by holders of a majority of the outstanding shares of Company Stock to adopt the Merger Agreement (the “Company Stockholder Approval”); (ii) the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (as amended), (the “HSR Act”); (iii) the absence of an order or law prohibiting the Merger or making consummation of the Merger illegal (a “Nonappealable Order”); and (iv) in the case of Campbell’s obligations to consummate the Merger, the absence of any events, occurrences, changes, state of circumstances or facts that would reasonably be expected to have a Company Material Adverse Effect (as defined in the Merger Agreement). Each party’s obligation to consummate the Merger is subject to certain other conditions, including the accuracy of the other party’s Merger Agreement representations and warranties (subject to materiality qualifiers) and the other party’s compliance with its Merger Agreement covenants and agreements in all material respects. Campbell and Merger Sub’s respective obligations to consummate the Merger are not subject to a financing condition.
Each of Campbell or the Company can terminate the Merger Agreement under certain circumstances, including (i) if the transactions contemplated by the Merger Agreement are not consummated on or before February 7, 2025, (ii) if a court of competent jurisdiction or other governmental authority in the United States has issued a final non-appealable, order, decree or injunction prohibiting or making illegal the consummation of, or enjoining the parties from consummating, the Merger, or (iii) if the Company Stockholder Approval did not occur. The Company may also terminate the Merger Agreement to accept a Superior Proposal (as defined in the Merger Agreement), subject to Campbell’s right to match such Superior Proposal, and Campbell may terminate the Merger Agreement if, among other things, the Company Board changes or fails to support the Company Board’s recommendation that the Merger Agreement be adopted by the Company’s stockholders (an “Adverse Recommendation Change”). The Company must pay Campbell a $71.3 million termination fee if the Company terminates the Merger Agreement to accept a Superior Proposal or if Campbell terminates the Merger Agreement because of an Adverse Recommendation Change, an alternative acquisition proposal has been publicly disclosed (and not withdrawn), the Merger Agreement is terminated and the Company consummates an alternative acquisition proposal, or signs a definitive agreement for an alternative acquisition proposal (that is subsequently consummated), within twelve months of such termination. Campbell must pay the Company a $145.0 million termination fee (minus any Reimbursed Expenses (as defined below)) if Campbell or the Company terminates the Merger Agreement because the Effective Time has not occurred before February 7, 2025, or if there is a Nonappealable Order (in each case, solely as a result of the failure to obtain the expiration or termination of the waiting period under the HSR Act or the issuance of an injunction or order, or the application of an applicable law or legal prohibition, relating to U.S. antitrust laws).
Parent is required to reimburse the Company for up to $10 million of the reasonable and documented fees and expenses incurred by the Company in connection with obtaining (or seeking to obtain) the expiration or termination of the applicable waiting period under the HSR Act (“Reimbursed Expenses”).
In connection with the Merger Agreement, (i) certain funds associated with Advent (such funds collectively, “Advent Funds”) that are stockholders of the Company and (ii) each member of the Company Board who holds Company Stock (together, the “Voting Parties”) have entered into a voting agreement with Parent (each, a “Voting Agreement”) and agreed, among other things, to vote the shares of Company Stock over which they have voting power to approve the Merger Agreement and the transactions contemplated thereby, including the Merger. Under the terms of each Voting Agreement, the relevant Voting Party has also agreed (a) to vote such Voting Party’s shares of Company Stock against any alternative acquisition proposal and (b) not to transfer its shares of Company Stock (subject to certain exceptions). In addition, the Advent Funds’ Voting Agreement contains a “no-shop” restriction that, among other things, prohibits such funds and their representatives from soliciting alternative acquisition proposals (subject to certain exceptions). As of August 7, 2023, the Voting Agreements cover approximately 34% of the shares of outstanding Company Stock. As of August 7, 2023, the Voting Parties collectively owned approximately 46% of the shares of outstanding Company Stock.
The foregoing does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Merger Agreement, which is included as Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the SEC on August 7, 2023. For the fiscal quarter ended July 1, 2023, the Company incurred legal expenses of $0.6 million associated with the pending Merger.
29
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q (“Form 10-Q”) contains forward-looking statements, including statements regarding the pending merger with Campbell Soup Company (“Campbell”). Forward-looking statements can be identified by words, such as “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects” and similar references to future periods, or by the inclusion of forecasts or projections. Examples of forward-looking statements include, but are not limited to, statements we make regarding the outlook for our future business and financial performance, such as those contained in this section.
Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. With respect to the pending Merger, these risks and uncertainties include, but are not limited to:
● | failure to obtain the required vote of the Company’s stockholders; |
● | the timing to consummate the proposed transaction; |
● | the risk that a condition to closing of the proposed transaction may not be satisfied or that the closing of the proposed transaction might otherwise not occur; |
● | the risk that a regulatory approval that may be required for the proposed transaction is not obtained or is obtained subject to conditions that are not anticipated; |
● | the diversion of management time on transaction-related issues; and |
● | the risk that the transaction and its announcement could have an adverse effect on the Company’s ability to retain customers and retain and hire key personnel. |
Other important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions and the following:
● | our dependence on third-party distributors and third-party co-packers, including one co-packer for the substantial majority of our Rao’s Homemade sauce products; |
● | adverse consequences of the actions of the major retailers, wholesalers, distributors and mass merchants on which we rely, including if they give higher priority to other brands or products, take steps to maintain or improve their margins by, among other things, raising the on-shelf prices of our products or imposing surcharges on us, or if they perform poorly or declare bankruptcy; |
● | inflation, including our vulnerability to decreases in the supply of and increases in the price of raw materials, packaging, fuel, labor, manufacturing, distribution and other costs, and our inability to offset increasing costs through cost savings initiatives or pricing; |
● | supply disruptions, including increased costs and potential adverse impacts on distribution and consumption; |
● | our inability to expand household penetration and successfully market our products; |
● | competition in the packaged food industry and our product categories; |
● | consolidation within the retail environment may allow our customers to demand lower pricing, increased promotional programs and increased deductions and allowances, among other items; |
● | our inability to successfully introduce new products or failure of recently launched products to meet expectations or remain on-shelf; |
● | our inability to accurately forecast pricing elasticities and the resulting impact on volume growth and/or distribution gains; |
● | failure by us or third-party co-packers or suppliers of raw materials to comply with labeling, food safety, environmental or other laws or regulations, or new laws or regulations; |
● | our vulnerability to the impact of severe weather conditions, natural disasters and other natural events such as herd, flock and crop diseases on our manufacturing facilities, co-packers or raw material suppliers; |
● | our inability to effectively manage our growth; |
● | fluctuations in currency exchange rates could adversely affect our results of operations and cash flows; |
● | geopolitical tensions, including relating to Ukraine; |
30
● | our inability to maintain our workforce; |
● | our inability to identify, consummate or integrate new acquisitions or realize the projected benefits of acquisitions; |
● | erosion of the reputation of one or more of our brands; |
● | our inability to protect ourselves from cyberattacks; |
● | failure to protect, or litigation involving, our tradenames or trademarks and other rights; |
● | our ability to effectively manage interest rate risk, including through the use of hedges and other strategies or financial products; |
● | the effects of climate change and adherence to environmental, social and governance demands; |
● | a change in assumptions used to value our goodwill or our intangible assets, or the impairment of our goodwill or intangible assets; |
● | our level of indebtedness under our Amended First Lien Credit Agreement (as defined herein), which as of July 1, 2023 was $480.8 million, and our duty to comply with covenants under our Amended First Lien Credit Agreement; |
● | the COVID-19 pandemic and associated effects; and |
● | the interests of our majority stockholder may differ from those of public stockholders. |
See Part I. Item IA. “Risk Factors” in our 2022 Form 10-K for a further description of these and other factors. For the reasons described above, our actual results may differ materially from those contemplated by the forward-looking statements. We caution you against relying on any forward-looking statements, which should also be read in conjunction with the other cautionary statements that are included elsewhere in this report. Any forward-looking statement made by us in this report speaks only as of the date on which we make it. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Unless the context otherwise requires, “we,” “us,” “our” and the “Company” refer to Sovos Brands, Inc. and its subsidiaries. The Company’s fiscal year ends on the last Saturday in December of each year and as a result, a 53rd week is added approximately every sixth year. Our fiscal year ended December 25, 2021 (“fiscal 2021”) had 52 weeks. Our fiscal year ended December 31, 2022 (“fiscal 2022”) had 53 weeks. Our fiscal year ending December 30, 2023 (“fiscal 2023”) will have 52 weeks. Our fiscal quarters are comprised of 13 weeks each, ending on the 13th Saturday of each quarter, except for the 53-week fiscal years for which the fourth quarter is comprised of 14 weeks, ending on the 14th Saturday of such fourth quarter. The information for the 13 weeks and 26 weeks ended July 1, 2023 and June 25, 2022 are derived from the unaudited condensed consolidated financial statements and the notes thereto included elsewhere in this report.
Overview
We are one of the fastest growing food companies of scale in the United States over the past two years, focused on growth of disruptive growth brands that bring today’s consumers great tasting food that fits the way they live. Our current brands, Rao’s, Michael Angelo’s and noosa are built with authenticity at their core, providing consumers food experiences that are genuine, delicious and unforgettable. Our premium products are made with simple, high-quality ingredients. We are focused on continuing to build an organization with the capabilities to acquire, integrate, and grow brands. We strive to empower our teams to lead with courage and tenacity, with the goal of providing them with the confidence and agility to connect with our consumers and retail partners to drive unparalleled growth. We believe our focus on “one-of-a-kind” brands and products that people love and our passion for our people make Sovos Brands a “one-of-a-kind” company and enables us to deliver on our objective of creating a growing and sustainable food enterprise yielding financial growth ahead of industry peers.
In September 2021, we completed our initial public offering (the “IPO”) and became actively traded on the Nasdaq Global Select Market (“Nasdaq”) listed under the trade symbol of “SOVO.”
31
On December 30, 2022, we completed our divestiture of Birch Benders which included the sale of the brand and certain related assets to Hometown Food Company, a portfolio company controlled by Brynwood Partners VIII L.P.
Pending Merger with Campbell
On August 7, 2023, we entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Campbell and Premium Products Merger Sub, Inc. (“Merger Sub”). Upon the terms and subject to the conditions stated in the Merger Agreement, Merger Sub will merge with and into the Company, and the Company will become a wholly owned subsidiary of Campbell (the “Merger”). The Company’s board of directors and the board of directors of Campbell have approved the Merger Agreement and the transactions described therein.
Pursuant to the Merger Agreement, at the effective time of the Merger (“Effective Time”), each issued and outstanding share of the Company’s common stock (“Company Stock”), except for certain shares of Company Stock specified in the Merger Agreement, will be canceled and automatically converted into the right to receive (i) $23.00 per share, and (ii) if the Merger is not effective by May 7, 2024, an additional $0.00182 per day beginning May 8, 2024, up to but excluding the date the Merger becomes effective.
The completion of the Merger is subject to customary closing conditions, including the adoption of the Merger Agreement by our stockholders. See Note 19. Subsequent Events of the Notes to Unaudited Condensed Consolidated Financial Statements. Note 19. Subsequent Events does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Merger Agreement, which is Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (“SEC”) on August 7, 2023. Upon consummation of the Merger, Sovos will cease to be a publicly traded company and our common stock will be delisted from Nasdaq.
Emerging Growth Status
Based on the aggregate worldwide market value of our shares of common stock held by our non-affiliate stockholders as of July 1, 2023, we expect that we will become a “large accelerated filer” and lose emerging growth status beginning with our Annual Report on Form 10-K for the year ended December 30, 2023. We will also no longer be exempt from the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002, as amended, and our independent registered public accounting firm will evaluate and report on the effectiveness of internal controls over financial reporting.
Market Trends
We continue to actively monitor the macroeconomic inflationary environment and the ongoing impacts to the global economy, including market disruptions, supply chain challenges and elevated costs, and consumer price sensitivity resulting from constrained purchasing power, as well as the level of consumer mobility, including the rate at which consumers return to working outside the home. Consistent with the consumer-packaged food industry, we are seeing a mix of cost increases, primarily across agricultural ingredients and labor, while we are also seeing favorability in specific ingredients, such as dairy and protein, as well as certain packaging materials including resin costs. Specific cost increases for the 26 weeks ended July 1, 2023 include, but are not limited to, tomatoes, fruit and cartons while other costs such as milk, protein and resin have decreased from the comparable period in fiscal 2022. In addition, the year over year cost of distribution for the 26 weeks ended July 1, 2023 has remained relatively flat, while in first half of fiscal 2022 ongoing logistical issues at major ports, intermodal and trucking delays and capacity constraints for ocean freight cargo resulted in increased distribution costs. In fiscal 2023, labor-related disruptions, including labor shortages and absenteeism, have been less challenging within our operations and among our third-party logistics and other business partners, compared to the prior year where we experienced elevated downtime in our plants, but remain challenging when compared to pre-pandemic levels.
During the 13 weeks and 26 weeks ended July 1, 2023, we experienced decreased cost of sales, as a percentage of net sales, driven by price increases in recent quarters across all products, changes in product mix, and productivity savings, all of which were partially offset by higher inflationary costs described above. Specifically, we benefited from pricing actions announced during the second half of 2022, as well as those taken during the first half of 2023, including the inflation-justified list price increases to our customers, for yogurt and frozen entrees that were implemented in February 2023.We also continue to execute various productivity and cost savings initiatives within our manufacturing and logistics network,
32
including further automation of our own production facilities, optimization of our co-manufacturing network, product and packaging value engineering, competitive procurement actions, and optimization of our logistics network. We continue to proactively manage cost inflation risk through forward purchase agreements, where possible, as well as through leveraging our scale and enhancing our relationships with our third-party manufacturing partners to lower the all-in costs to manufacture our products. Collectively, we expect the pricing actions, productivity initiatives and value engineering that we have implemented to date to mitigate the ongoing increases in costs.
We expect year-over-year inflationary pressures to continue through the remainder of fiscal 2023, and that they will be relatively consistent throughout the full fiscal year 2023. As a result, we have and will continue to closely monitor our pricing.
Based on the information available to us as of the date of this Report, we believe that we will be able to deliver products at acceptable levels to fulfill customer orders on a timely basis. Therefore, we expect our products will continue to be available for purchase to meet consumer needs. We will continue to monitor customer and consumer demand along with our supply chain and logistics capabilities and intend to adapt our plans as needed to continue to drive our business and meet our obligations.
Key Performance Indicators
We regularly review a number of metrics to evaluate our business, measure our progress and make strategic decisions. EBITDA, Adjusted EBITDA, EBITDA margin, Adjusted EBITDA margin, adjusted gross profit, adjusted gross margin, adjusted operating expenses, adjusted operating income, adjusted income tax (expense), adjusted effective tax rate, adjusted net income, and diluted earnings per share from adjusted net income (the “non-GAAP financial measures”), which are non-GAAP financial measures, are currently utilized by management and may be used by our competitors to assess performance. We believe these measures assist our investors in gaining a meaningful understanding of our performance. Because not all companies use identical calculations, our presentation of these measures may not be comparable to other similarly titled measures of other companies. See “—Non-GAAP Financial Measures” for definitions and a reconciliation of net income (loss) to EBITDA and Adjusted EBITDA, gross profit to adjusted gross profit, total operating expenses to adjusted operating expenses, operating income (loss) to adjusted operating income, reported income tax (expense) benefit to adjusted income tax (expense), reported effective tax rate to adjusted effective tax rate, net income (loss) to adjusted net income and diluted earnings per share to diluted earnings per share from adjusted net income.
33
Results of Operations
The discussion that follows includes a comparison of our results of operations and liquidity and capital resources for the 13 weeks and 26 weeks ended July 1, 2023 and June 25, 2022.
Comparison of Unaudited Results for the 13 weeks ended July 1, 2023 and June 25, 2022
The following unaudited table presents, for the periods indicated, selected information from our Condensed Consolidated Statements of Operations, including information presented as a percentage of net sales:
13 Weeks Ended | 13 Weeks Ended | Increase / (Decrease) |
| |||||||||||||||
(In thousands, except share and per share data) | July 1, 2023 | % of Net Sales | June 25, 2022 | % of Net Sales | $ Change | % Change |
| |||||||||||
| ||||||||||||||||||
Net sales | $ | 217,635 |
| 100.0 | % | $ | 197,433 |
| 100.0 | % | $ | 20,202 |
| 10.2 | % | |||
Cost of sales |
| 146,928 |
| 67.5 | % |
| 142,410 |
| 72.1 | % |
| 4,518 |
| 3.2 | % | |||
Gross profit |
| 70,707 |
| 32.5 | % |
| 55,023 |
| 27.9 | % |
| 15,684 |
| 28.5 | % | |||
Operating expenses: |
|
|
|
|
|
|
|
| ||||||||||
Selling, general and administrative |
| 47,633 |
| 21.9 | % |
| 39,449 |
| 20.0 | % |
| 8,184 |
| 20.7 | % | |||
Depreciation and amortization |
| 6,004 |
| 2.8 | % |
| 7,200 |
| 3.6 | % |
| (1,196) |
| (16.6) | % | |||
Impairment of goodwill | — | — | % | 42,052 | 21.3 | % | (42,052) | (100.0) | % | |||||||||
Total operating expenses |
| 53,637 |
| 24.7 | % |
| 88,701 |
| 44.9 | % |
| (35,064) |
| (39.5) | % | |||
Operating income (loss) |
| 17,070 |
| 7.8 | % |
| (33,678) |
| (17.1) | % |
| 50,748 |
| 150.7 | % | |||
Interest expense, net |
| 8,678 |
| 4.0 | % |
| 5,713 |
| 2.9 | % |
| 2,965 |
| 51.9 | % | |||
Income (loss) before income taxes |
| 8,392 |
| 3.8 | % |
| (39,391) |
| (20.0) | % |
| 47,783 |
| 121.3 | % | |||
Income tax (expense) benefit |
| (3,003) |
| (1.4) | % |
| 9,106 |
| 4.6 | % |
| 12,109 |
| 133.0 | % | |||
Net income (loss) | $ | 5,389 |
| 2.4 | % | $ | (30,285) |
| (15.3) | % | $ | 35,674 |
| 117.8 | % | |||
Diluted earnings (loss) per share | $ | 0.05 | $ | (0.30) | $ | 0.35 | 116.7 | % | ||||||||||
Diluted weighted average shares outstanding | 103,271,838 | 100,897,815 | 2,374,023 | 2.4 | % | |||||||||||||
Other financial data: (1) |
|
|
|
|
|
|
|
| ||||||||||
EBITDA | $ | 25,634 |
| 11.8 | % | $ | (23,853) |
| (12.1) | % | $ | 49,487 |
| 207.5 | % | |||
Adjusted EBITDA | $ | 35,166 |
| 16.2 | % | $ | 25,691 |
| 13.0 | % | $ | 9,475 |
| 36.9 | % | |||
Adjusted gross profit | $ | 70,707 | 32.5 | % | $ | 55,225 | 28.0 | % | $ | 15,482 | 28.0 | % | ||||||
Adjusted operating expenses | $ | 38,499 | 17.7 | % | $ | 32,549 | 16.5 | % | $ | 5,950 | 18.3 | % | ||||||
Adjusted operating income | $ | 32,208 | 14.8 | % | $ | 22,676 | 11.5 | % | $ | 9,532 | 42.0 | % | ||||||
Adjusted income tax (expense) | $ | (6,094) | (2.8) | % | $ | (4,261) | (2.2) | % | $ | 1,833 | 43.0 | % | ||||||
Adjusted net income | $ | 17,436 | 8.0 | % | $ | 12,702 | 6.4 | % | $ | 4,734 |
| 37.3 | % | |||||
Diluted earnings per share from adjusted net income | $ | 0.17 | $ | 0.13 | $ | 0.04 | 30.8 | % |
(1) | Other financial data includes non-GAAP financial metrics. See “Non-GAAP Financial Measures” for definitions and a reconciliation of our net income (loss) to EBITDA and Adjusted EBITDA, net income (loss) to adjusted net income, total operating expenses to adjusted operating expenses, reported income tax (expense) benefit to adjusted income tax (expense) and reported effective tax rate to adjusted effective tax rate. |
Net Sales
Net sales consist primarily of product sales to our customers less cost of trade promotions such as consumer incentives, coupon redemptions, other in-store merchandising activities and allowances for unsalable product.
Net sales of $217.6 million represented an increase of $20.2 million, or 10.2%, for the 13 weeks ended July 1, 2023, as compared to the 13 weeks ended June 25, 2022. The increase was driven by 8.9% volume growth and 7.4% price and mix from our Rao’s, noosa and Michael Angelo’s brands combined. These increases were partially offset by a 6.1% decrease in net sales for Birch Benders due to the divestiture of the brand and certain related assets on December 30, 2022. Net sales growth from a brand perspective was led by Rao’s up 29.3% as a result of higher sales across the entire brand, most notably sauce. Additionally, noosa grew 0.9% while Michael Angelo’s declined 23.4%. Michael Angelo’s net sales decline in the quarter was primarily driven by the decision to eliminate certain channel specific, lower margin frozen entrée
34
products, as well as the impact of lapping the year-ago period when the Company cancelled nearly all of its promotions due to supply chain issues.
Cost of Sales
Cost of sales represents costs directly related to the manufacturing and distribution of products. Such costs include raw materials, labor and overhead required to produce the products, co-manufacturing, packaging, warehousing, shipping and handling, third-party distribution, and depreciation of equipment and leasehold improvements. We manufacture our products in our Austin, Texas and Bellvue, Colorado manufacturing locations. We also use third-party contract manufacturers in the United States, Canada and the European Union. We procure selected elements of raw materials and packaging and receive finished goods. We incur tolling charges related to our contract manufacturing arrangements.
Cost of sales of $146.9 million represented an increase of $4.5 million, or 3.2%, for the 13 weeks ended July 1, 2023 as compared to the 13 weeks ended June 25, 2022. The increase was primarily attributable to volume growth, which was partially offset by productivity savings, mostly within our manufacturing network, as well as the inclusion of cost of sales in the prior year period from the Birch Benders brand which was, along with certain related assets, divested on December 30, 2022. We also experienced increased costs associated with agricultural ingredients, predominantly related to tomatoes and fruit, as well as labor.
Cost of sales as a percentage of net sales decreased from 72.1% for the 13 weeks ended June 25, 2022, to 67.5% for the 13 weeks ended July 1, 2023. The decrease in cost of sales as a percentage of net sales was driven by the contribution to net sales from higher pricing and mix, as well as productivity savings, all of which were partially offset by higher inflationary costs as described above.
Gross Profit
Gross profit of $70.7 million represented an increase of $15.7 million, or 28.5%, for the 13 weeks ended July 1, 2023, as compared to the 13 weeks ended June 25, 2022. Gross profit as a percentage of net sales, or gross margin, increased from 27.9% for the 13 weeks ended June 25, 2022 to 32.5% for the 13 weeks ended July 1, 2023, and was a result of the items discussed above.
Operating Expenses
Operating expenses of $53.6 million represented a decrease of $35.1 million, or 39.5%, for the 13 weeks ended July 1, 2023 compared to the 13 weeks ended June 25, 2022 due to the following:
● | Selling, General and Administrative expenses: Selling, general and administrative expenses include sales and marketing costs and general and administrative expenses, including expenses for employee salaries and benefits. Selling and marketing costs also include advertising and marketing costs, broker commissions and research and development expenses. General and administrative expenses are also comprised of expenses associated with our corporate and administrative functions that support our business, including equity-based compensation expense, professional services, including legal, audit and tax compliance fees and third-party consultancy fees, insurance and other corporate expenses. |
Selling, general and administrative expenses of $47.6 million represented an increase of $8.2 million, or 20.7%, for the 13 weeks ended July 1, 2023 compared to the 13 weeks ended June 25, 2022. The increase was primarily driven by: (a) increased spending, including professional fees, of $4.5 million to support marketing, research and development and selling; (b) increased employee-related expenses of $2.6 million; and (c) higher equity-based compensation expense of $1.9 million. These increases were offset by a decrease of $0.9 million because of the Birch Benders divestiture at the end of fiscal 2022 primarily related to selling expenses for broker costs and product development costs.
The higher selling, marketing, and research and development expenses are primarily due to our increased investment in our marketing activities to support recently launched innovations from our current portfolio,
35
including Michael Angelo’s sauce and Rao’s frozen pizza, and product development activities to support product line extensions and new products, as well as increased selling costs driven by the increase in sales volumes. The increase in employee-related expenses is primarily due to increased headcount, higher incentive compensation accruals as a result of year-to-date performance and increased meeting and travel-related expenses as the COVID-related travel restrictions ease. The increase in equity-based compensation expense is due to recognizing expense for new equity awards made during the 13 weeks ended July 1, 2023 and the new equity awards and equity modifications made since June 25, 2022.
● | Depreciation and Amortization expenses: Depreciation and amortization expense consists of the depreciation of non-production property and equipment, including leasehold improvements, equipment, capitalized leases and the amortization of customer relationships and finite-lived trademarks. |
Depreciation and amortization expenses of $6.0 million represented a decrease of $1.2 million, or 16.6%, for the 13 weeks ended July 1, 2023, compared to the 13 weeks ended June 25, 2022. The decrease was primarily related to a reduction in amortization expense for the 13 weeks ended July 1, 2023 due to the sale of the Birch Benders intangible assets in conjunction with the divestiture in December 2022.
● | Impairment of Goodwill: We test our goodwill for impairment at least annually, or when circumstances indicate that the carrying amount of the asset may not be recoverable and record any related impairment loss as an expense. For the 13 weeks ended June 25, 2022, we recognized an impairment charge of $42.1 million in connection with the impairment of the Birch Benders goodwill due to the underperformance of the brand. No impairment changes were recorded for the 13 weeks ended July 1, 2023. |
Interest Expense, Net
Interest expense, net primarily consists of interest and fees on our Credit Facilities (as defined herein) and amortization of deferred financing costs, offset by investment income. We have incurred, and may incur additional, indebtedness to fund acquisitions, and we may choose to prepay on our Credit Facilities to reduce indebtedness.
Interest expense, net of $8.7 million represented an increase of $3.0 million, or 51.9%, for the 13 weeks ended July 1, 2023 compared to the 13 weeks ended June 25, 2022. The increase in interest expense is primarily due to an increase in variable interest rates on our Credit Facilities. The weighted average rate for the 13 weeks ended July 1, 2023 was 8.76% compared to a weighted average rate of 4.36% for the 13 weeks ended June 25, 2022. The impact of the rate increase was partially offset by our interest rate hedge. Refer to Note 13. Hedging and Derivative Financial Instruments to the condensed consolidated financial statements in this Form 10-Q for further discussion on our cash flow hedge of interest rate risk. The Credit Facilities interest expense was offset by higher realized investment interest income in the 13 weeks ended July 1, 2023, due to a higher cash balance available to invest, along with higher interest rates on investments.
Income Tax (Expense) Benefit
Income tax (expense) benefit consists of federal and various state taxes. Income tax (expense) of $3.0 million represented an increase of $12.1 million for the 13 weeks ended July 1, 2023 compared to the 13 weeks ended June 25, 2022. The increase was primarily driven by higher income before taxes and the loss of a tax benefit from the impairment of goodwill in 2022.
Net Income (Loss)
Net income for the 13 weeks ended July 1, 2023was $5.4 million compared to net loss of $30.3 million for the 13 weeks ended June 25, 2022. The increase in net income was attributable to the items described above.
36
Other Financial Data
See “—Non-GAAP Financial Measures” for discussions of:
● | EBITDA and Adjusted EBITDA and a reconciliation of our net income (loss) to EBITDA and Adjusted EBITDA; |
● | adjusted gross profit and a reconciliation of our gross profit to adjusted gross profit; |
● | adjusted operating expenses and a reconciliation of our total operating expenses to adjusted operating expenses; |
● | adjusted operating income and a reconciliation of our total operating income (loss) to adjusted operating income; |
● | adjusted income tax (expense) and a reconciliation of our reported income tax (expense) benefit to adjusted income tax (expense); |
● | adjusted effective tax rate and a reconciliation of reported effective tax rates to adjusted effective tax rate; |
● | adjusted net income and a reconciliation of our net income (loss) to adjusted net income and; |
● | diluted earnings per share from adjusted net income and a reconciliation of our net income (loss) and the associated diluted loss per share to adjusted net income and the associated diluted earnings per share. |
37
Comparison of Unaudited Results for the 26 weeks ended July 1, 2023 and June 25, 2022
The following unaudited table presents, for the periods indicated, selected information from our Condensed Consolidated Statements of Operations, including information presented as a percentage of net sales:
26 Weeks Ended |
| 26 Weeks Ended | Increase / (Decrease) |
| ||||||||||||||
(In thousands, except share and per share data) | July 1, 2023 | % of Net sales | June 25, 2022 | % of Net sales | $ Change | % Change |
| |||||||||||
| ||||||||||||||||||
Net sales | $ | 470,426 |
| 100.0 | % | $ | 407,366 |
| 100.0 | % | $ | 63,060 |
| 15.5 | % | |||
Cost of sales |
| 328,907 |
| 69.9 | % |
| 298,435 |
| 73.3 | % |
| 30,472 |
| 10.2 | % | |||
Gross profit |
| 141,519 |
| 30.1 | % |
| 108,931 |
| 26.7 | % |
| 32,588 |
| 29.9 | % | |||
Operating expenses: |
|
|
|
|
|
|
|
| ||||||||||
Selling, general and administrative |
| 91,047 |
| 19.4 | % |
| 73,364 |
| 18.0 | % |
| 17,683 |
| 24.1 | % | |||
Depreciation and amortization |
| 11,984 |
| 2.5 | % |
| 14,403 |
| 3.5 | % |
| (2,419) |
| (16.8) | % | |||
Impairment of goodwill | — | — | % | 42,052 | 10.3 | % | (42,052) | (100.0) | % | |||||||||
Total operating expenses |
| 103,031 |
| 21.9 | % |
| 129,819 |
| 31.9 | % |
| (26,788) |
| (20.6) | % | |||
Operating income (loss) |
| 38,488 |
| 8.2 | % |
| (20,888) |
| (5.1) | % |
| 59,376 |
| 284.3 | % | |||
Interest expense, net |
| 17,379 |
| 3.7 | % |
| 11,735 |
| 2.9 | % |
| 5,644 |
| 48.1 | % | |||
Income (loss) before income taxes |
| 21,109 |
| 4.5 | % |
| (32,623) |
| (8.0) | % |
| 53,732 |
| 164.7 | % | |||
Income tax (expense) benefit |
| (7,874) |
| (1.7) | % |
| 6,395 |
| 1.6 | % |
| 14,269 |
| 223.1 | % | |||
Net income (loss) | $ | 13,235 |
| 2.8 | % | $ | (26,228) |
| (6.4) | % | $ | 39,463 |
| 150.5 | % | |||
|
|
|
|
|
|
|
| |||||||||||
Diluted earnings (loss) per share | $ | 0.13 | $ | (0.26) | $ | 0.39 | 150.0 | % | ||||||||||
Diluted weighted average shares outstanding | 102,389,768 | 100,895,181 | 1,494,587 | 1.5 | % | |||||||||||||
Other financial data: (1) | ||||||||||||||||||
EBITDA | $ | 55,521 |
| 11.8 | % | $ | (1,508) |
| (0.4) | % | $ | 57,029 |
| NM | % | |||
Adjusted EBITDA | $ | 71,121 |
| 15.1 | % | $ | 53,312 |
| 13.1 | % | $ | 17,809 |
| 33.4 | % | |||
Adjusted gross profit | $ | 141,797 | 30.1 | % | $ | 109,725 | 26.9 | % | $ | 32,072 | 29.2 | % | ||||||
Adjusted operating expenses(2) | $ | 76,497 | 16.3 | % | $ | 62,174 | 15.3 | % | $ | 14,323 | 23.0 | % | ||||||
Adjusted operating income | $ | 65,300 | 13.9 | % | $ | 47,551 | 11.7 | % | $ | 17,749 | 37.3 | % | ||||||
Adjusted income tax (expense) | $ | (12,363) | (2.6) | % | $ | (9,332) | (2.3) | % | $ | 3,031 | 32.5 | % | ||||||
Adjusted net income | $ | 35,558 |
| 7.6 | % | $ | 26,484 |
| 6.5 | % | $ | 9,074 |
| 34.3 | % | |||
Diluted earnings per share from adjusted net income | $ | 0.35 | $ | 0.26 | $ | 0.09 | 34.6 | % |
NM- Not meaningful.
(1) | Other financial data includes non-GAAP financial metrics. See “Non-GAAP Financial Measures” for definitions and a reconciliation of our net income (loss) to EBITDA and Adjusted EBITDA, net income (loss) to adjusted net income, total operating expenses to adjusted operating expenses, reported income tax (expense) benefit to adjusted income tax (expense) and reported effective tax rate to adjusted effective tax rate. |
Net Sales
Net sales consist primarily of product sales to our customers less cost of trade promotions such as consumer incentives, coupon redemptions, other in-store merchandising activities and allowances for unsalable product.
Net sales of $470.4 million represented an increase of $63.1 million, or 15.5%, for the 26 weeks ended July 1, 2023, as compared to the 26 weeks ended June 25, 2022. The increase was driven by 12.5% volume growth and 9.2% price and mix from our Rao’s, noosa and Michael Angelo’s brands combined. These increases were partially offset by a 6.2% decrease in net sales for Birch Benders due to the divestiture of the brand and certain related assets on December 30, 2022. Net sales growth from a brand perspective was led by Rao’s up 33.8% as a result of higher sales across the entire brand, most notably sauce. Additionally, noosa grew 4.3% while Michael Angelo’s declined 14.4%. Michael Angelo’s net sales decline in the 26 weeks ended July 1, 2023 was primarily driven by the decision to eliminate certain channel specific,
38
lower margin frozen entrée products, as well as the impact of lapping the year-ago period when the Company cancelled nearly all of its promotions due to supply chain issues.
Cost of Sales
Cost of sales represents costs directly related to the manufacturing and distribution of products. Such costs include raw materials, labor and overhead required to produce the products, co-manufacturing, packaging, warehousing, shipping and handling, third-party distribution, and depreciation of equipment and leasehold improvements. We manufacture our products in our Austin, Texas and Bellvue, Colorado manufacturing locations. We also use third-party contract manufacturers in the United States, Canada and the European Union. We procure selected elements of raw materials and packaging and receive finished goods. We incur tolling charges related to our contract manufacturing arrangements.
Cost of sales of $328.9 million represented an increase of $30.5 million, or 10.2%, for the 26 weeks ended July 1, 2023 as compared to the 26 weeks ended June 25, 2022. The increase was primarily attributable to volume growth, which was partially offset by productivity savings, mostly within our manufacturing network, as well as the inclusion of cost of sales in the prior year period from the Birch Benders brand which was, along with certain related assets, divested on December 30, 2022. We also experienced increased costs associated with agricultural ingredients, predominantly related to tomatoes and fruit, as well as labor.
Cost of sales as a percentage of net sales decreased from 73.3% for the 26 weeks ended June 25, 2022, to 69.9% for the 26 weeks ended July 1, 2023. The decrease in cost of sales as a percentage of net sales was driven by the contribution to net sales from higher pricing and mix, as well as productivity savings, all of which were partially offset by higher inflationary costs as described above.
Gross Profit
Gross profit of $141.5 million represented an increase of $32.6 million, or 29.9%, for the 26 weeks ended July 1, 2023, as compared to the 26 weeks ended June 25, 2022. Gross profit as a percentage of net sales, or gross margin, increased from 26.7% for the 26 weeks ended June 25, 2022 to 30.1% for the 26 weeks ended July 1, 2023, and was a result of the items discussed above.
Operating Expenses
Operating expenses of $103.0 million represented a decrease of $26.8 million, or 20.6%, for the 26 weeks ended July 1, 2023 compared to the 26 weeks ended June 25, 2022 due to the following:
● | Selling, General and Administrative expenses: Selling, general and administrative expenses include sales and marketing costs and general and administrative expenses, including expenses for employee salaries and benefits. Selling and marketing costs also include advertising and marketing costs, broker commissions and research and development expenses. General and administrative expenses are also comprised of expenses associated with our corporate and administrative functions that support our business, including equity-based compensation expense, professional services, including legal, audit and tax compliance fees and third-party consultancy fees, insurance and other corporate expenses. |
Selling, general and administrative expenses of $91.0 million represented an increase of $17.7 million, or 24.1%, for the 26 weeks ended July 1, 2023 compared to the 26 weeks ended June 25, 2022. The increase was primarily driven by: (a) increased spending, including professional fees, of $9.0 million to support marketing, research and development and selling; (b) increased employee-related expenses of $8.1 million; and (c) higher equity-based compensation expense of $3.3 million. These increases were offset by a decrease of $2.8 million because of the Birch Benders divestiture at the end of fiscal 2022 primarily related to selling expenses for broker costs and product development costs.
The higher selling, marketing, and research and development expenses are primarily due to our increased investment in our marketing activities to support recently launched innovations to our current portfolio,
39
including Michael Angelo’s sauce and Rao’s frozen pizza, and product development activities to support product line extensions and new products, as well as increased selling costs driven by the increase in sales volumes. The increase in employee-related expenses is primarily due to increased headcount, higher incentive compensation accruals as a result of year-to-date performance and increased meeting and travel-related expenses as the COVID-related travel restrictions ease. The increase in equity-based compensation expense is due to recognizing expense for new equity awards and equity modifications made during the 26 weeks ended July 1, 2023.
● | Depreciation and Amortization expenses: Depreciation and amortization expense consists of the depreciation of non-production property and equipment, including leasehold improvements, equipment, capitalized leases and the amortization of customer relationships and finite-lived trademarks. |
Depreciation and amortization expenses of $12.0 million represented a decrease of $2.4 million, or 16.8%, for the 26 weeks ended July 1, 2023, compared to the 26 weeks ended June 25, 2022. The decrease was primarily related to a reduction in amortization expense for the 26 weeks ended July 1, 2023 due to the sale of the Birch Benders intangible assets in conjunction with the divestiture in December 2022.
● | Impairment of Goodwill: We test our goodwill for impairment at least annually, or when circumstances indicate that the carrying amount of the asset may not be recoverable and record any related impairment loss as an expense. For the 26 weeks ended June 25, 2022, we recognized an impairment charge of $42.1 million in connection with the impairment of Birch Benders goodwill due to the underperformance of the brand. No impairment changes were recorded for the 26 weeks ended July 1, 2023. |
Interest Expense, Net
Interest expense, net primarily consists of interest and fees on our Credit Facilities (as defined herein) and amortization of deferred financing costs, offset by investment income. We have incurred, and may incur additional, indebtedness to fund acquisitions, and we may choose to prepay on our Credit Facilities to reduce indebtedness.
Interest expense, net of $17.4 million represented an increase of $5.6 million, or 48.1%, for the 26 weeks ended July 1, 2023 compared to the 26 weeks ended June 25, 2022. The increase in interest expense is primarily due to an increase in variable interest rates on our Credit Facilities. The weighted average rate for the 26 weeks ended July 1, 2023 was 8.53% compared to a weighted average rate of 4.45% for the 26 weeks ended June 25, 2022. The impact of the rate increase was partially offset by our interest rate hedge. Refer to Note 13. Hedging and Derivative Financial Instruments to the condensed consolidated financial statements in this Form 10-Q for further discussion on our cash flow hedge of interest rate risk. The Credit Facilities interest expense was offset by higher realized investment interest income in the 26 weeks ended July 1, 2023, due to a higher cash balance available to invest, along with higher interest rates on investments.
Income Tax (Expense) Benefit
Income tax (expense) benefit consists of federal and various state taxes. Income tax (expense) of $7.9 million represented an increase of $14.3 million for the 26 weeks ended July 1, 2023 compared to the 26 weeks ended June 25, 2022. The increase was primarily driven by higher income before taxes, the loss of a tax benefit from the impairment of goodwill in 2022 and the higher limitation on the deduction of executive compensation for public companies.
Net Income (Loss)
Net income for the 26 weeks ended July 1, 2023 was $13.2 million compared to net loss of $26.2 million for the 26 weeks ended June 25, 2022. The increase in net income was attributable to the items described above.
Other Financial Data
See “—Non-GAAP Financial Measures” for discussions of:
40
● | EBITDA and Adjusted EBITDA and a reconciliation of our net income (loss) to EBITDA and Adjusted EBITDA; |
● | adjusted gross profit and a reconciliation of our gross profit to adjusted gross profit; |
● | adjusted operating expenses and a reconciliation of our total operating expenses to adjusted operating expenses; |
● | adjusted operating income and a reconciliation of our total operating income (loss) to adjusted operating income; |
● | adjusted income tax (expense) and a reconciliation of our reported income tax (expense) benefit to adjusted income tax (expense); |
● | adjusted effective tax rate and a reconciliation of reported effective tax rates to adjusted effective tax rate; |
● | adjusted net income and a reconciliation of our net income (loss) to adjusted net income and; |
● | diluted earnings per share from adjusted net income and a reconciliation of our net income (loss) and the associated diluted loss per share to adjusted net income and the associated diluted earnings per share. |
Non-GAAP Financial Measures
We report our financial results in accordance with GAAP. To supplement this information, we also use EBITDA, Adjusted EBITDA, EBITDA margin, Adjusted EBITDA margin, adjusted gross profit, adjusted gross margin, adjusted operating expenses, adjusted operating income, adjusted income tax (expense), adjusted effective tax rate, adjusted net income, and diluted earnings per share from adjusted net income, non-GAAP financial measures, in this report. We define EBITDA as net income (loss) before net interest expense, income tax (expense) benefit, depreciation and amortization. We define Adjusted EBITDA as EBITDA adjusted for non-cash equity-based compensation costs, non-recurring costs, gain (loss) on foreign currency contracts, supply chain optimization costs, impairment of goodwill, transaction and integration costs and IPO readiness costs. EBITDA margin is determined by calculating the percentage EBITDA is of net sales. Adjusted EBITDA margin is determined by calculating the percentage Adjusted EBITDA is of net sales. Adjusted gross margin is determined by calculating the percentage of adjusted gross profit is of net sales. Adjusted gross profit, adjusted operating expenses, adjusted operating income, adjusted income tax (expense) and adjusted effective tax rate, and adjusted net income consists of gross profit, total operating expenses, operating income (loss), reported income tax (expense) benefit, reported effective tax rate, and net income (loss) before non-cash equity-based compensation costs, non-recurring costs, gain (loss) on foreign currency contracts, supply chain optimization costs, impairment of goodwill, transaction and integration costs, IPO readiness costs, acquisition amortization and tax-related adjustments that we do not consider in our evaluation of our ongoing operating performance from period to period as discussed further below. Diluted earnings per share from adjusted net income is determined by dividing adjusted net income by the weighted average diluted shares outstanding. Non-GAAP financial measures are included in this report because they are key metrics used by management to assess our operating performance. Management believes that non-GAAP financial measures are helpful in highlighting performance trends because non-GAAP financial measures eliminate non-recurring and unusual items and non-cash expenses, which we do not consider indicative of ongoing operational performance. Our presentation of non-GAAP financial measures should not be construed to imply that our future results will be unaffected by these items. By providing these non-GAAP financial measures, management believes we are enhancing investors’ understanding of our business and our results of operations, as well as assisting investors in evaluating how well we are executing our strategic initiatives.
EBITDA, Adjusted EBITDA, EBITDA margin, Adjusted EBITDA margin, adjusted gross profit, adjusted gross margin, adjusted operating expenses, adjusted operating income, adjusted income tax (expense), adjusted effective tax rate, adjusted net income and diluted earnings per share from adjusted net income are not defined under GAAP. Our use of the terms EBITDA, Adjusted EBITDA, EBITDA margin, Adjusted EBITDA margin, adjusted gross profit, adjusted gross margin, adjusted operating expenses, adjusted operating income, adjusted income tax (expense), adjusted effective tax rate, adjusted net income and diluted earnings per share from adjusted net income may not be comparable to similarly titled measures of other companies in our industry and are not measures of performance calculated in accordance with GAAP. Our presentation of non-GAAP financial measures is intended to provide supplemental measures of our performance that are not required by, or presented in accordance with, GAAP. Non-GAAP financial measures should not
41
be considered as alternatives to operating income (loss), net income (loss), earnings (loss) per share, net sales or any other performance measures derived in accordance with GAAP, or as measures of operating cash flows or liquidity.
Non-GAAP financial measures have important limitations as analytical tools, and you should not consider them in isolation or as substitutes for analysis of our results as reported under GAAP. Some of these limitations are:
● | EBITDA, Adjusted EBITDA, EBITDA margin and Adjusted EBITDA margin do not reflect any charges for the assets being depreciated and amortized that may need to be replaced in the future; |
● | Adjusted operating income, adjusted income tax (expense), adjusted effective tax rate and adjusted net income do not reflect any charges for acquisition amortization; |
● | EBITDA, Adjusted EBITDA, EBITDA margin and Adjusted EBITDA margin do not reflect the significant interest expense or the cash requirements necessary to service interest or, if any, principal payments on our debt; |
● | EBITDA, Adjusted EBITDA, EBITDA margin and Adjusted EBITDA margin do not reflect our income tax (expense) benefit or the cash requirements to pay our income taxes; |
● | Adjusted EBITDA, Adjusted EBITDA margin, adjusted operating expenses, adjusted operating income, adjusted income tax (expense), adjusted effective tax rate, adjusted net income and diluted earnings per share from adjusted net income do not reflect the impact of non-cash equity-based compensation upon our results of operations; |
● | Adjusted EBITDA, Adjusted EBITDA margin, adjusted operating expenses, adjusted operating income, adjusted income tax (expense), adjusted effective tax rate, adjusted net income and diluted earnings per share from adjusted net income do not include certain expenses that are non-recurring, infrequent and unusual in nature, costs related to loss on extinguishment of debt, professional fees related to organizational optimization, costs for capital markets-related activities and enterprise resource planning (“ERP”) conversion costs related to integrating acquisitions; |
● | Adjusted EBITDA, Adjusted EBITDA margin, adjusted operating expenses, adjusted operating income, adjusted income tax (expense), adjusted effective tax rate, adjusted net income and diluted earnings per share from adjusted net income do not reflect the impact of unrealized gain (loss) on foreign currency contracts; |
● | Adjusted EBITDA, Adjusted EBITDA margin, adjusted gross profit, adjusted gross margin, adjusted operating expenses, adjusted operating income, adjusted income tax (expense), adjusted effective tax rate, adjusted net income and diluted earnings per share from adjusted net income do not reflect the impact of supply chain initiatives associated with packaging optimization and a strategic initiative to move co-packaging production from an international supplier to a domestic supplier; |
● | Adjusted EBITDA, Adjusted EBITDA margin, adjusted operating expenses, adjusted operating income, adjusted income tax (expense), adjusted effective tax rate, adjusted net income and diluted earnings per share from adjusted net income do not reflect the impact of impairments of goodwill; |
● | Adjusted EBITDA, Adjusted EBITDA margin, adjusted gross profit, adjusted gross margin, adjusted operating expenses, adjusted operating income, adjusted income tax (expense), adjusted effective tax rate, adjusted net income and diluted earnings per share from adjusted net income do not reflect the impact of transaction and integration costs associated with acquisitions and divestitures and costs associated with potential or uncompleted transactions; and |
● | Adjusted EBITDA, Adjusted EBITDA margin, adjusted operating expenses, adjusted operating income, adjusted income tax (expense), adjusted effective tax rate, adjusted net income and diluted earnings per share |
42
from adjusted net income do not reflect costs associated with public company readiness and other professional fees associated with building the organizational infrastructure to support a public company environment. |
In the future we may incur expenses similar to those eliminated in this presentation of non-GAAP financial measures.
43
The following table provides a reconciliation of EBITDA and Adjusted EBITDA to net income, their most directly comparable GAAP measure, for each of the periods presented:
13 Weeks Ended | 26 Weeks Ended | ||||||||||||||||||||||||
(In thousands) |
| July 1, 2023 | % of Net sales |
| June 25, 2022 | % of Net sales | July 1, 2023 |
| % of Net sales |
| June 25, 2022 |
| % of Net sales | ||||||||||||
Net income (loss)(1) | $ | 5,389 | 2.4 | % | $ | (30,285) | (15.3) | % | $ | 13,235 | 2.8 | % | $ | (26,228) | (6.4) | % | |||||||||
Interest expense, net | 8,678 | 4.0 | 5,713 | 2.9 |
| 17,379 | 3.7 |
| 11,735 | 2.9 | |||||||||||||||
Income tax (expense) benefit | (3,003) | (1.4) | 9,106 | 4.6 |
| (7,874) | (1.7) |
| 6,395 | 1.6 | |||||||||||||||
Depreciation and amortization | 8,564 | 3.9 | 9,825 | 5.0 |
| 17,033 | 3.6 |
| 19,380 | 4.8 | |||||||||||||||
EBITDA(1) | 25,634 | 11.7 | (23,853) | (12.1) |
| 55,521 | 11.8 |
| (1,508) | (0.4) | |||||||||||||||
Non-cash equity-based compensation(2) | 6,419 | 3.0 | 4,547 | 2.3 |
| 11,927 | 2.6 |
| 8,634 | 2.1 | |||||||||||||||
Non-recurring costs(3) | 1,807 | 0.9 | 2,023 | 1.0 |
| 2,034 | 0.4 |
| 2,400 | 0.6 | |||||||||||||||
Loss on foreign currency contracts(4) | 331 | 0.2 | 497 | 0.3 | 198 | — | 497 | 0.1 | |||||||||||||||||
Supply chain optimization(5) | — | — | 202 | 0.1 |
| 128 | — |
| 794 | 0.2 | |||||||||||||||
Impairment of goodwill(6) | — | — | 42,052 | 21.3 |
| — | — |
| 42,052 | 10.3 | |||||||||||||||
Transaction and integration costs(7) | 975 | 0.4 | 59 | 0 |
| 1,313 | 0.3 |
| 59 | — | |||||||||||||||
Initial public offering readiness(8) | — | — | 164 | 0.1 |
| — | — |
| 384 | 0.1 | |||||||||||||||
Adjusted EBITDA(1) | $ | 35,166 | 16.2 | % | $ | 25,691 | 13.0 | % | $ | 71,121 | 15.1 | % | $ | 53,312 | 13.1 | % |
(1) | Net income (loss) as a percentage of net sales is also referred to as net income (loss) margin. EBITDA and Adjusted EBITDA as a percentage of net sales are also referred to as EBITDA margin and Adjusted EBITDA margin. |
(2) | Consists of non-cash equity-based compensation expense associated with the grant of equity-based compensation provided to officers, non-employee directors and employees. |
(3) | Consists of costs for professional fees related to organizational optimization and capital markets activities. |
(4) | Consists of unrealized loss on foreign currency contracts. |
(5) | Consists of write-downs associated with packaging optimization and a strategic initiative to move co-packaging production from an international supplier to a domestic supplier. |
(6) | Consists of expenses for impairment of goodwill. |
(7) | Consists of costs associated with the divestiture of the Birch Benders brand and certain related assets, and costs associated with potential transactions, including the pending Merger. |
(8) | Consists of costs associated with building the organizational infrastructure to support a public company environment. |
The following tables provide a reconciliation of adjusted gross profit, adjusted operating expenses, adjusted operating income, adjusted interest expense, net, adjusted income tax (expense) and adjusted net income to their most directly comparable GAAP measure, for each of the periods presented:
44
13 Weeks Ended | |||||||||||||||||||
(In thousands, except share and per share data) | July 1, 2023 | ||||||||||||||||||
| Gross profit |
| Operating expenses |
| Operating income |
| Interest expense, net |
| Income tax (expense) |
| Net income |
| |||||||
As reported (GAAP) | $ | 70,707 | $ | 53,637 | $ | 17,070 | $ | 8,678 | $ | (3,003) | $ | 5,389 | |||||||
Adjustments: | |||||||||||||||||||
Non-cash equity-based compensation(1) |
| — | (6,419) | 6,419 | — | — |
| 6,419 | |||||||||||
Non-recurring costs(2) |
| — | (1,807) | 1,807 | — | — |
| 1,807 | |||||||||||
Loss on foreign currency contracts(3) | — | (331) | 331 | — | — | 331 | |||||||||||||
Transaction and integration costs(6) |
| — | (975) | 975 | — | — |
| 975 | |||||||||||
Acquisition amortization(8) | — | (5,606) | 5,606 | — | — | 5,606 | |||||||||||||
Tax effect of adjustments(9) |
| — | — | — | — | (2,957) |
| (2,957) | |||||||||||
One-time tax (expense) items(10) | — | — | — | — | (134) | (134) | |||||||||||||
As adjusted | $ | 70,707 | $ | 38,499 | $ | 32,208 | $ | 8,678 | $ | (6,094) | $ | 17,436 | |||||||
As adjusted (% of net sales) | 32.5 | %(11) | 17.7 | % | 14.8 | % |
| 4.0 | % | (2.8) | % |
| 8.0 | % | |||||
Earnings per share: | |||||||||||||||||||
Diluted |
| 0.05 | |||||||||||||||||
Adjusted diluted |
| 0.17 | |||||||||||||||||
Weighted average shares outstanding: | |||||||||||||||||||
Diluted for net income | 103,271,838 | ||||||||||||||||||
Diluted for adjusted net income | 103,271,838 |
13 Weeks Ended | |||||||||||||||||||
(In thousands, except share and per share data) | June 25, 2022 | ||||||||||||||||||
| Gross profit |
| Operating expenses |
| Operating income (loss) |
| Interest expense, net |
| Income tax (expense) benefit |
| Net income (loss) |
| |||||||
As reported (GAAP) | $ | 55,023 | $ | 88,701 | $ | (33,678) | $ | 5,713 | $ | 9,106 | $ | (30,285) | |||||||
Adjustments: | |||||||||||||||||||
Non-cash equity-based compensation(1) |
| — | (4,547) | 4,547 | — | — |
| 4,547 | |||||||||||
Non-recurring costs(2) |
| — | (2,023) | 2,023 | — | — |
| 2,023 | |||||||||||
Loss on foreign currency contracts(3) | — | (497) | 497 | — | — | 497 | |||||||||||||
Supply chain optimization(4) |
| 202 | — | 202 | — | — |
| 202 | |||||||||||
Impairment of goodwill(5) | — | (42,052) | 42,052 | — | — | 42,052 | |||||||||||||
Transaction and integration costs(6) |
| — | (59) | 59 | — | — |
| 59 | |||||||||||
Initial public offering readiness(7) |
| — | (164) | 164 | — | — |
| 164 | |||||||||||
Acquisition amortization(8) | — | (6,810) | 6,810 | — | — | 6,810 | |||||||||||||
Tax effect of adjustments(9) |
| — | — | — | — | (3,091) |
| (3,091) | |||||||||||
One-time tax (expense) items(10) | — | — | — | — | (10,276) | (10,276) | |||||||||||||
As adjusted | $ | 55,225 | $ | 32,549 | $ | 22,676 | $ | 5,713 | $ | (4,261) | $ | 12,702 | |||||||
As adjusted (% of net sales) | 28.0 | %(11) | 16.5 | % | 11.5 | % |
| 2.9 | % | (2.2) | % |
| 6.4 | % | |||||
Earnings (loss) per share: | |||||||||||||||||||
Diluted |
| (0.30) | |||||||||||||||||
Adjusted diluted |
| 0.13 | |||||||||||||||||
Weighted average shares outstanding: | |||||||||||||||||||
Diluted for net income | 100,897,815 | ||||||||||||||||||
Diluted for adjusted net income | 101,321,056 |
45
26 Weeks Ended | |||||||||||||||||||
(In thousands, except share and per share data) | July 1, 2023 | ||||||||||||||||||
| Gross profit |
| Operating expenses |
| Operating income |
| Interest expense, net |
| Income tax (expense) |
| Net income |
| |||||||
As reported (GAAP) | $ | 141,519 | $ | 103,031 | $ | 38,488 | $ | 17,379 | $ | (7,874) | $ | 13,235 | |||||||
Adjustments: | |||||||||||||||||||
Non-cash equity-based compensation(1) |
| — | (11,927) | 11,927 | — | — |
| 11,927 | |||||||||||
Non-recurring costs(2) |
| — | (2,034) | 2,034 | — | — |
| 2,034 | |||||||||||
Loss on foreign currency contracts(3) | — | (198) | 198 | — | — | 198 | |||||||||||||
Supply chain optimization(4) |
| 128 | — | 128 | — | — |
| 128 | |||||||||||
Transaction and integration costs(6) |
| 150 | (1,163) | 1,313 | — | — |
| 1,313 | |||||||||||
Acquisition amortization(8) | — | (11,212) | 11,212 | — | — | 11,212 | |||||||||||||
Tax effect of adjustments(9) |
| — | — | — | — | (4,334) |
| (4,334) | |||||||||||
One-time tax (expense) benefit items(10) | — | — | — | — | (155) | (155) | |||||||||||||
As adjusted | $ | 141,797 | $ | 76,497 | $ | 65,300 | $ | 17,379 | $ | (12,363) | $ | 35,558 | |||||||
As adjusted (% of net sales) | 30.1 | %(11) | 16.3 | % | 13.9 | % |
| 3.7 | % | (2.6) | % |
| 7.6 | % | |||||
Earnings per share: | |||||||||||||||||||
Diluted |
| 0.13 | |||||||||||||||||
Adjusted diluted |
| 0.35 | |||||||||||||||||
Weighted average shares outstanding: | |||||||||||||||||||
Diluted for net income | 102,389,768 | ||||||||||||||||||
Diluted for adjusted net income | 102,389,768 |
26 Weeks Ended | |||||||||||||||||||
(In thousands, except share and per share data) | June 25, 2022 | ||||||||||||||||||
Gross profit | Operating expenses | Operating income (loss) | Interest expense, net | Income tax (expense) benefit | Net income (loss) | ||||||||||||||
As reported (GAAP) | $ | 108,931 | $ | 129,819 | $ | (20,888) | $ | 11,735 | $ | 6,395 | $ | (26,228) | |||||||
Adjustments: | |||||||||||||||||||
Non-cash equity-based compensation(1) |
| — | (8,634) | 8,634 | — | — |
| 8,634 | |||||||||||
Non-recurring costs(2) |
| — | (2,400) | 2,400 | — | — |
| 2,400 | |||||||||||
Loss on foreign currency contracts(3) | — | (497) | 497 | — | — | 497 | |||||||||||||
Supply chain optimization(4) |
| 794 | — | 794 | — | — |
| 794 | |||||||||||
Impairment of goodwill(5) | — | (42,052) | 42,052 | — | — | 42,052 | |||||||||||||
Transaction and integration costs(6) |
| — | (59) | 59 | — | — |
| 59 | |||||||||||
Initial public offering readiness(7) |
| — | (384) | 384 | — | — |
| 384 | |||||||||||
Acquisition amortization(8) | — | (13,619) | 13,619 | — | — | 13,619 | |||||||||||||
Tax effect of adjustments(9) |
| — | — | — | — | (5,451) |
| (5,451) | |||||||||||
One-time tax (expense) items(10) | — | — | — | — | (10,276) | (10,276) | |||||||||||||
As adjusted | $ | 109,725 | $ | 62,174 | $ | 47,551 | $ | 11,735 | $ | (9,332) | $ | 26,484 | |||||||
As adjusted (% of net sales) | 26.9 | %(11) | 15.3 | % | 11.7 | % |
| 2.9 | % | (2.3) | % |
| 6.5 | % | |||||
Earnings (loss) per share: | |||||||||||||||||||
Diluted |
| (0.26) | |||||||||||||||||
Adjusted diluted |
| 0.26 | |||||||||||||||||
Weighted average shares outstanding: | |||||||||||||||||||
Diluted for net income | 100,895,181 | ||||||||||||||||||
Diluted for adjusted net income | 101,053,289 |
(1) | Consists of non-cash equity-based compensation expense associated with the grant of equity-based compensation provided to officers, non-employee directors and employees. |
(2) | Consists of costs for professional fees related to organizational optimization and capital markets activities. |
46
(3) | Consists of unrealized loss on foreign currency contracts. |
(4) | Consists of write-downs associated with packaging optimization and a strategic initiative to move co-packaging production from an international supplier to a domestic supplier. |
(5) | Consists of expenses for impairment of goodwill. |
(6) | Consists of costs associated with the divestiture of the Birch Benders brand and certain related assets and costs associated with potential transactions, including the pending Merger. |
(7) | Consists of costs associated with building the organizational infrastructure to support a public company environment. |
(8) | Amortization costs associated with acquired trade names and customer lists. |
(9) | Tax effect was calculated using the Company's adjusted annual effective tax rate. |
(10) | Represents the removal of the tax effect of impairment of goodwill, removal for remeasurement of deferred taxes related to intangibles for changes in deferred rate, the removal of the tax effect of non-deductible transaction costs and the removal of the excess tax benefits related to equity-based compensation vesting. |
(11) | Adjusted gross profit as a percentage of net sales is also referred to as adjusted gross margin. |
We adjust the GAAP financial measures for reported income tax (expense) benefit and reported effective tax rate to exclude the effect of non-cash equity-based compensation costs, other non-recurring costs, loss on foreign currency contracts, supply chain optimization costs, impairment of goodwill, transaction and integration costs, IPO readiness costs, and acquisition amortization impacting comparability. We excluded the items which we believe may obscure trends in our pre-tax income and the related tax effect of those items on our adjusted effective tax rate and other impacts to tax expense. This non-GAAP financial measure is intended to provide a meaningful comparison of the Company’s effective tax rate, excluding the pre-tax income and tax effect of the items noted above, for the periods presented. Management uses this non-GAAP financial measure to monitor the effectiveness of adjustments on our tax rate.
The following table provides reconciliations of reported income tax (expense) benefit to adjusted income tax (expense) and reported effective tax rate to adjusted effective tax rate for the 13 weeks and 26 weeks ended July 1, 2023 and June 25, 2022:
13 Weeks Ended | 26 Weeks Ended | |||||||||||||
(In thousands) | July 1, 2023 | June 25, 2022 |
| July 1, 2023 |
| June 25, 2022 | ||||||||
Reported income tax (expense) benefit | $ | (3,003) | $ | 9,106 | $ | (7,874) | $ | 6,395 | ||||||
Non-cash equity-based compensation | — | (703) | — | (703) | ||||||||||
Non-recurring costs | (542) | (440) | (597) | (440) | ||||||||||
Loss on foreign currency contracts | — | (121) | — | (121) | ||||||||||
Supply chain optimization | — | (195) | (31) | (195) | ||||||||||
Impairment of goodwill | — | (10,276) | — | (10,276) | ||||||||||
Transaction and integration costs | (310) | 401 | (310) | (15) | ||||||||||
Initial public offering readiness | — | (99) | — | (447) | ||||||||||
Acquisition amortization | (2,239) | (1,934) | (3,551) | (3,530) | ||||||||||
Adjusted income tax (expense)(1) | $ | (6,094) | $ | (4,261) | $ | (12,363) | $ | (9,332) | ||||||
Reported effective tax rate | 35.8 | % | 23.1 | % | 37.3 | % | 19.6 | % | ||||||
Non-cash equity-based compensation | — | 0.1 | — | 0.3 | ||||||||||
Non-recurring costs | (1.7) | 0.1 | (1.5) | 0.2 | ||||||||||
Loss on foreign currency contracts | — | — | — | 0.1 | ||||||||||
Supply chain optimization | — | — | (0.1) | 0.1 | ||||||||||
Impairment of goodwill | — | 1.5 | — | 4.2 | ||||||||||
Transaction and integration costs | (1.0) | (0.1) | (0.8) | — | ||||||||||
Initial public offering readiness | — | — | — | 0.2 | ||||||||||
Acquisition amortization | (7.2) | 0.3 | (9.1) | 1.4 | ||||||||||
Adjusted effective tax rate(1) | 25.9 | % | 25.0 | % | 25.8 | % | 26.1 | % |
(1) | The adjustments to reported income tax (expense) benefit and reported effective tax rate represent the tax effect of the reconciling items included in the reconciliation tables above for adjusted gross profit, adjusted operating expenses, adjusted operating income, adjusted interest expense, net, adjusted income tax (expense) and adjusted net income to their most directly comparable GAAP measure. See “—Non-GAAP Financial |
47
Measures” for definitions of our reported income tax (expense) benefit to adjusted income tax (expense) and reported effective tax rate to adjusted effective tax rate. |
Liquidity and Capital Resources
Our primary sources of liquidity include cash flow from operations, cash and cash equivalents and credit capacity under our Credit Facilities. As of July 1, 2023, we had cash and equivalents of $169.6 million and availability under our Credit Facilities of $125.0 million.
We expect to use cash primarily for working capital, capital expenditures, purchase commitments, lease obligations, interest payments on our debt and potential acquisitions. We estimate that our capital expenditures will be approximately $11 million to $13 million in fiscal 2023, which we plan to fund with cash generated from our operating activities. The principal balance on our Initial First Lien Term Loan Facility was $480.8 million as of July 1, 2023, with no obligation to pay principal payments over the remaining term. At a minimum, we are required to make quarterly interest payments and estimate our interest payments to be approximately $39 million to $41 million over the next 12 months. Our total lease obligations were $22.7 million as of July 1, 2023, with $3.3 million due over the next 12 months. We have purchase commitments of approximately $4.7 million and $8.4 million to third-party and related-party manufacturers and suppliers, respectively, over the next 12 months, primarily for materials and supplies used in the manufacture of our products.
We also have long-term cash requirements related to our purchase commitments, lease obligations and principal payments on our debt. See Note 9. Long-Term Debt, Note 10. Leases, Note 11. Commitments and Contingencies and Note 17. Related Party Transactions for additional discussion related to the expected timing and amount of payments related to our contractual obligations.
We believe that our cash flow from operations, availability under our Revolving Facility (as defined herein) and available cash and cash equivalents will be sufficient to meet our liquidity needs for at least the next 12 months. We anticipate that to the extent that we require additional liquidity, it will be funded through the incurrence of additional indebtedness, the issuance of equity, or a combination thereof. We cannot assure you that we will be able to obtain this additional liquidity on reasonable terms, or at all. Additionally, our liquidity and our ability to meet our obligations and fund our capital requirements are also dependent on our future financial performance, which is subject to general economic, financial and other factors that are beyond our control. Accordingly, we cannot assure you that our business will generate sufficient cash flow from operations or that future borrowings will be available from additional indebtedness or otherwise to meet our liquidity needs. We may incur additional debt or sell additional equity to finance future acquisitions, which would result in additional expenses or dilution.
Merger-related Liquidity and Capital Resources Limitations
We have agreed to various agreements and covenants in the Merger Agreement, including among others, agreements to conduct our business in the ordinary course during the period between the execution of the Merger Agreement and either the Effective Time or the valid termination of the Merger Agreement pursuant to its terms. Outside of certain limited exceptions, we may not take or agree to take certain actions without Campbell’s consent, including acquiring businesses, entering into certain specified contracts, making unbudgeted capital expenditures, issuing additional capital stock or securities convertible into capital stock, or incurring additional indebtedness. We do not believe these restrictions will prevent us from meeting our ongoing operating expenses, working capital needs, or capital expenditure requirements.
Credit Facilities and Unused Borrowing Capacity
In June 2021, Sovos Intermediate (the “Borrower”) entered into (i) the First Lien Credit Agreement, pursuant to which the First Lien Lenders agreed to provide senior secured credit facilities, consisting of (a) an initial first lien term loan facility in an original principal amount of $580.0 million (the “Initial First Lien Term Loan Facility” and the loans thereunder, the “Initial First Lien Term Loans”) and (b) a revolving facility in an original principal amount of $125.0 million (the “Revolving Facility” and the loans thereunder, the “Revolving Loans”), including a letter of credit facility with a $45.0 million sublimit (the Initial First Lien Term Loan Facility and the Revolving Facility, collectively, the “Credit Facilities”).
48
In 2021, we prepaid $99.2 million of the outstanding principal balance under the Initial First Lien Term Loans. As a result of the prepayment on the Initial First Lien Term Loans, all future principal payments have been eliminated for the remaining term of the loan.
On June 28, 2023, Sovos Intermediate amended the First Lien Credit Agreement. The amended First Lien Credit Agreement (“Amended First Lien Credit Agreement”) replaces the London Inter-Bank Offered Rate (“LIBO Rate”) for loans denominated in dollars with a successor rate based on Term Secured Overnight Financing Rate (“Term SOFR”).
The interest rate for the Initial First Lien Term Loans and the Revolving Loans is (at the Borrower's option) either (a) LIBO Rate (as defined in the Amended First Lien Credit Agreement) plus the applicable LIBO Rate spread or (b) Alternate Base Rate (as defined in the Amended First Lien Credit Agreement) plus the applicable Alternate Base Rate spread. As of June 28, 2023, Term SOFR (as defined in the Amended First Lien Credit Agreement) replaced the LIBO Rate as the base rate for loans denominated in dollars. However, to the extent any LIBO Rate loan denominated in dollars was outstanding on June 28, 2023, such loan shall continue to bear interest at the LIBO Rate until the end of the current interest period or payment period applicable to such loan and such loan shall be governed by the terms of First Lien Credit Agreement applicable to LIBO Rate loans denominated in dollars until the earlier of (i) the repayment of such loans or (ii) the conversion of such loans into Term SOFR loans or ABR loans. Effective as of June 28, 2023, a credit spread adjustment (0.11448% per annum for one month tenor, 0.26161% per annum for a three month tenor, 0.42826% per annum for a six month tenor and 0.71513% per annum for a twelve month tenor) shall apply to Term SOFR loans pursuant to the Amended First Lien Credit Agreement. The Initial First Lien Term Loans mature on June 8, 2028 and any Revolving Loans mature on June 8, 2026.
As of July 1, 2023, we have available credit of $125.0 million under the Revolving Facility. No revolving loans were outstanding as of July 1, 2023. As of July 1, 2023 and December 31, 2022, the effective interest rate for the Initial First Lien Term Loans and Revolving Facility was 8.77% and 7.91%, respectively.
The Amended First Lien Credit Agreement contains various financial, affirmative and negative covenants that we must adhere to. Under the Amended First Lien Credit Agreement, the Borrower is required to comply with a springing financial covenant, which requires the Borrower to maintain a first lien net leverage ratio of consolidated first lien net debt to consolidated EBITDA (with certain adjustments as set forth in the Amended First Lien Credit Agreement) of no greater than 6.95:1.00. Such financial covenant is tested only if outstanding revolving loans (excluding any undrawn letters of credit) minus unrestricted cash exceeds 35% of the aggregate revolving credit commitments. The financial covenant is subject to customary “equity cure” rights. In addition, under the Amended First Lien Credit Agreement, an annual excess cashflow calculation is required, to determine if any excess is required to be paid on the Initial First Lien Term Loan Facility. As of July 1, 2023, the Company had no outstanding revolving loans, so did not meet the requirement to test the financial covenant under the Amended First Lien Credit Agreement.
Statement of Cash Flows
The following table presents a summary of our cash flows provided by (used in) operating, investing and financing activities for the periods presented:
26 Weeks Ended | ||||||
(In thousands) | July 1, 2023 |
| June 25, 2022 | |||
Cash provided by (used in): |
|
|
|
| ||
Operating activities | $ | 34,583 | $ | 16,274 | ||
Investing activities |
| (3,571) |
| (9,730) | ||
Financing activities |
| (41) |
| (47) | ||
Change in cash and cash equivalents | $ | 30,971 | $ | 6,497 |
Cash Provided by Operating Activities
Cash provided by operating activities was $34.6 million for the 26 weeks ended July 1, 2023, an increase of $18.3 million from $16.3 million for the 26 weeks ended June 25, 2022. The increase was primarily due to an increase in net income (loss) of $39.5 million and a decrease in adjustments to reconcile net income (loss) to net cash provided by
49
operating activities of $29.9 million, plus an increase in cash provided by changes in operating assets and liabilities of $8.7 million.
The decrease in adjustments to reconcile net income (loss) to net cash provided by operating activities of $29.9 million was primarily related to $42.1 million impairment of goodwill in the 26 weeks ended June 25, 2022, offset by increases in deferred taxes and equity-based compensation related to new equity awards and equity modifications made during the 26 weeks ended July 1, 2023.
The increase in cash provided by changes in operating assets and liabilities of $8.7 million for the 26 weeks ended July 1, 2023 was primarily due to an increase in cash of $23.0 million from accounts receivable resulting from increased sales volumes and improved collections, and an increase in cash provided by inventories of $8.4 million due to less inventory build in the 26 weeks ended July 1, 2023 compared to the 26 weeks ended June 25, 2022, primarily due to strong sales volumes. The increase in cash provided by accounts receivable and inventories for the 26 weeks ended July 1, 2023 was offset by an increase in the use of cash for accounts payable of $14.5 million, an increased use of cash for accrued expenses of $4.8 million related primarily to compensation and trade promotions plus an increase in the use of cash for prepaid expenses of $3.3 million related primarily to prepaid insurance, trade and marketing.
Cash Used in Investing Activities
Cash used in investing activities was $3.6 million for the 26 weeks ended July 1, 2023, a decrease of $6.1 million from $9.7 million for the 26 weeks ended June 25, 2022. The decrease was related to decreased cash used for capital expenditures, primarily due to prior year payments for new production equipment at a co-packing manufacturing facility and packaging automation at our Austin, Texas manufacturing facility.
Cash Used in Financing Activities
Cash used in financing activities was $41 thousand for the 26 weeks ended July 1, 2023, a decrease of $6 thousand from $47 thousand for the 26 weeks ended June 25, 2022. Financing activities consisted of repayments of capital lease obligations.
Off-Balance Sheet Arrangements
As of July 1, 2023, we had no off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, income or expenses, results of operations, liquidity, capital expenditures or capital resources.
Critical Accounting Estimates
There were no material changes from the Critical Accounting Estimates disclosed in our Annual Report on Form 10-K, filed with the SEC on March 8, 2023.
Recently Issued Accounting Pronouncements
See Note 2. Summary of Significant Accounting Policies, to the condensed consolidated financial statements included in this Form 10-Q for a discussion of recently issued accounting pronouncements.
50
Item 3.Quantitative and Qualitative Disclosures about Market Risk
We are exposed to the following market risks:
Commodity and Packaging Prices and Inflation
In the 26 weeks ended July 1, 2023, we experienced decreased cost of sales, as a percentage of net sales, driven by price increases in recent quarters across all products, changes in product mix, and productivity savings, all of which were partially offset by higher inflationary costs. Consistent with the consumer-packaged food industry, we are experiencing a mix of cost increases in several raw materials and packaging while other costs are flat or lower than the prior year. Specific cost increases for the 26 weeks ended July 1, 2023 include, but are not limited to, tomatoes, fruit and cartons while costs such as milk, proteins and resin have decreased from the comparable period in fiscal 2022. In addition, the year over year cost of distribution for the 26 weeks ended July 1, 2023 has remained relatively flat, while in first half of fiscal 2022 logistical issues at major ports, intermodal and trucking delays and capacity constraints for ocean freight cargo resulted in increased distribution costs.
Interest Rate Risk
We are exposed to interest rate risk through fluctuations in interest rates on our debt obligations. Interest rate changes do not affect the market value of such debt, but could impact the amount of our interest payments, and accordingly, our future earnings and cash flows, assuming other factors are held constant. As of July 1, 2023, we had $480.8 million of variable rate debt outstanding under our Credit Facilities. See “Liquidity and Capital Resources — Credit Facilities and Unused Borrowing Capacity” above. As of July 2022, we entered into a cash flow hedge to manage interest rate risk on $240.0 million of the $480.8 million variable rate debt. Based upon our principal amount of long-term debt outstanding at July 1, 2023, a hypothetical 1% increase or 1% decrease in average interest rates over a LIBOR base or Term SOFR base of 5.27% would impact our annual interest expense in the next year by approximately $2 million.
Foreign Currency Exchange Risk
The Company is exposed to certain risks relating to its ongoing business operations including foreign currency exchange rate risk. Fluctuations in foreign currency exchange rates could result in, among other things, our paying higher prices for certain imported products and services, and realizing lower net income, on a U.S. dollar basis, from our international purchases. For additional information regarding our foreign currency exchange risk refer to Note 13. Hedging and Derivative Financial Instruments, to the condensed consolidated financial statements in this Form 10-Q.
Item 4.Controls and Procedures
We maintain disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are designed to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required financial disclosures.
Management, including the participation of our Chief Executive Officer and our Chief Financial Officer, conducted an evaluation (pursuant to Rule 13a-15(b) under the Exchange Act) of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of July 1, 2023, the Company’s disclosure controls and procedures were effective.
Changes in Internal Control over Financial Reporting
There were no changes in our internal controls over financial reporting during the 13 weeks ended July 1, 2023 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.
51
PART II. Other Information
Item 1. Legal Proceedings
From time to time, we may become involved in actions, claims, suits and other legal proceedings arising in the ordinary course of our business, including lawsuits or claims relating to product labelling or related disclaimers, product recalls and product liability as well as the marketing of our products, intellectual property, contracts, employment matters, environmental matters or other aspects of our business. We are not currently a party to any actions the outcome of which would, individually or in the aggregate, have a material adverse effect on our business, financial condition and results of operations if determined adversely to us.
Item 1A. Risk Factors
Our operations and financial results are subject to various risks and uncertainties. Other than as set forth below related to the proposed transaction with Campbell, including the merger of the Company with a wholly owned subsidiary of Campbell, there were no material changes from the risk factors discussed in Part I, Item 1A., “Risk Factors” in our 2022 Form 10-K.
Risks Related to the Proposed Transaction with Campbell.
The announcement and pendency of the pending Merger may have an adverse effect on our business, results of operations, and financial condition, whether or not the Merger is completed, and our failure to complete the Merger could have an adverse effect on our business, results of operation, financial condition, and stock price.
On August 7, 2023, we announced that we had entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among the Company, Campbell and Merger Sub. Upon the terms and subject to the conditions stated in the Merger Agreement, Merger Sub will merge with and into the Company (the “Merger”), and the Company will become a wholly owned subsidiary of Campbell. Uncertainty about the effect of the Merger on our key suppliers, customers, brokers, employees, and other parties may adversely affect our business, results of operations, and financial condition. We could potentially lose employees, suppliers, customers or brokers, or our suppliers, customers or brokers could adversely modify their relationships with us or performance for us. In addition, we have devoted, and will continue to devote, significant management resources to complete the Merger and related transactions. This may cause our business and operating results to suffer. Losses of suppliers, customers, brokers or employees, or other important strategic relationships could have a material adverse effect on our business, results of operations, and financial condition. Such adverse effects could also be exacerbated by a delay in the completion of the Merger for any reason, including delays associated with obtaining requisite regulatory approvals or the approval of our stockholders.
The Merger Agreement also places restrictions on how we conduct our business before the Merger is effective. These restrictions could result in our inability to respond efficiently and successfully to competitive pressures, industry developments and future opportunities. This could harm our business, results of operations, and financial condition.
If the Merger does not become effective, or during the pendency of the Merger, we may suffer other consequences that could adversely affect our business, results of operations, financial condition, and stock price, and our stockholders would be exposed to additional risks, including:
● | to the extent that the current market price of Company Stock reflects an assumption that the Merger will be completed, the market price of Company Stock could decrease if the Merger is not completed; |
● | investor confidence in us could decline if the Merger is not completed; |
● | we may be unable to retain key personnel (either during the pendency of the Merger or if the Merger is not completed), and our results of operations may be adversely impacted due to costs incurred in connection with the Merger; |
● | stockholder litigation; |
52
● | any disruptions to our business resulting from the announcement and pendency of the Merger, including adverse changes in our relationships with suppliers, customers, brokers, employees and other parties may continue or intensify in the event the Merger is not consummated or is significantly delayed; |
● | the risks related to the diversion of attention of our management or employees during the pendency of the Merger; and |
● | the requirement that we pay Campbell a termination fee of $71.3 million under certain circumstances that give rise to the termination of the Merger Agreement. |
Even if the Merger is successfully completed:
● | receipt of the all-cash per share Merger consideration is generally taxable to stockholders that are treated as U.S. holders for U.S. federal income tax purposes; and |
● | stockholders will forego the opportunity to realize the potential long-term value of the successful execution of our current strategy as a public company. |
As a result of the Merger, our current and prospective employees could experience uncertainty about their future with us. As a result, key employees may depart because of issues relating to such uncertainty or a desire not to remain with Campbell following the completion of the Merger.
As a result of the Merger, our current and prospective employees could experience uncertainty about their future with us or decide that they do not want to continue their employment with the surviving company. As a result, key employees may depart because of issues relating to such uncertainty or a desire not to remain with Campbell following the completion of the Merger. Losses of officers, key employees or other employees could materially harm our business, results of operations, and financial condition. Such adverse effects could also be exacerbated by a delay in the completion of the Merger for any reason, including delays associated with obtaining requisite regulatory approvals or the approval of our stockholders. We may also experience challenges in hiring new employees during the pendency of the Merger, or if the Merger Agreement is terminated, which could harm our ability to grow our business, execute on our business plans or enhance our operations.
The consummation of the Merger is contingent upon the satisfaction of a number of conditions, including stockholder and regulatory approvals, that may be outside of our or Campbell’s control and that we and Campbell may be unable to satisfy or obtain or which may delay the consummation of the Merger or result in the imposition of conditions that could reduce the anticipated benefits from the Merger or cause the parties to abandon the Merger.
Consummation of the Merger is contingent upon the satisfaction of a number of conditions, some of which are beyond our and Campbell’s control, including, among others:
● | the adoption of the Merger Agreement by the holders of a majority of outstanding shares of Company Stock; |
● | the expiration or early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended; and |
● | the absence of an order or law prohibiting or making consummation of the Merger illegal. |
These conditions to the closing of the Merger may not be fulfilled in a timely manner or at all, and, accordingly, the Merger may not be completed.
We and Campbell may also be subject to lawsuits challenging the Merger, and adverse rulings in these lawsuits may delay or prevent the Merger from being completed or require us or Campbell to incur significant costs to defend or settle these lawsuits. Any delay in completing the Merger could cause us not to realize, or to be delayed in realizing, some or all of the benefits that we expect to achieve if the Merger is successfully completed within its expected time frame.
53
The Merger Agreement contains provisions that could discourage or deter a potential competing offer to acquire the Company’s common stock.
We are not permitted to solicit proposals for certain alternative business combination transactions and, subject to certain exceptions, we are not permitted to engage in discussions or negotiations regarding an alternative business combination transaction. We are required to hold a meeting of our stockholders to vote on the adoption of the Merger Agreement. In addition, in certain circumstances if we terminate the Merger Agreement, we may be required to pay a termination fee. Such restrictions could discourage or deter a third party, that may be willing to pay more than Campbell for our outstanding Company Stock, from considering or proposing such an acquisition.
Litigation could arise in connection with the Merger, which could be costly, prevent consummation of the Merger, divert management’s attention and otherwise materially harm our business.
To our knowledge, as of the date of this Quarterly Report on Form 10-Q no complaints have been properly filed against us seeking to enjoin the Merger or other relief. However, if litigation related to the Merger is commenced, any such litigation may be time-consuming and expensive and may distract our management from running the day-to-day operations of our business. The litigation costs and diversion of management’s attention and resources to address the claims and counterclaims in any litigation related to the Merger may materially adversely affect our business, results of operations, prospects, and financial condition. If the Merger is not consummated for any reason, litigation could be filed in connection with the failure to consummate the Merger. Any litigation related to the Merger may result in negative publicity or an unfavorable impression of us, which could adversely affect the price of Company Stock, impair our ability to recruit or retain employees, damage our relationships with our customers, suppliers, brokers and other business partners, or otherwise materially harm our operations and financial performance.
A significant portion of our outstanding shares of Company Stock is controlled by a few entities, and their interests may conflict with those of other stockholders.
As of August 4, 2023, Advent beneficially owned in the aggregate approximately 43.0% of our outstanding common stock. As a result, Advent may be able to exercise significant influence over us and certain matters requiring the approval of our stockholders, including the approval of significant corporate transactions, such as a merger or other sale of the Company or its assets. This could limit the ability of our other stockholders to influence corporate matters and may have the effect of delaying or preventing a third party from acquiring control of our Company. In addition, Advent may have actual or potential interests that diverge from the interests of our other stockholders.
On August 7, 2023, certain funds affiliated with Advent entered into a voting agreement with Campbell, pursuant to which such funds agreed, among other things, to vote certain shares of Company Stock over which they have voting power to approve the Merger Agreement and the transactions contemplated thereby, including the Merger.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not Applicable.
54
Item 5. Other Information
Rule 10b5-1 Trading Plans
During the 13 weeks ended July 1, 2023, none of our directors or officers (as defined in Ruel 16a-1(f) under the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” in accordance with Item 408 of Regulation S-K.
55
Item 6. Exhibits
Exhibit | ||
No. |
| Document |
2.1 | ||
* 10.1 | ||
*†10.2 | ||
*†10.3 | ||
*†10.4 | ||
10.5 | ||
10.6 | ||
*31.1 | ||
*31.2 | ||
*32.1 | ||
101.INS | XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | |
101.SCH | XBRL Taxonomy Extension Schema Document | |
101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document | |
101.DEF | XBRL Taxonomy Extension Definition Linkbase Document | |
101.LAB | XBRL Taxonomy Extension Label Linkbase Document | |
101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101). | |
* Filed herewith.
† Management contract or compensatory plan or arrangement. |
56
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Sovos Brands, Inc. | ||
By: | /s/ Christopher W. Hall | |
Date: August 9, 2023 | Name: | Christopher W. Hall |
Title: | Chief Financial Officer | |
(Principal Financial Officer and Authorized Officer) |
57